Interpace Biosciences (IDXG) 10-K/A 19 Jan 21 2019 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Apr. 17, 2020	Jun. 30, 2019
Cover [Abstract]
Entity Registrant Name	INTERPACE BIOSCIENCES, INC.
Entity Central Index Key	0001054102
Document Type	10-K/A
Document Period End Date	Dec. 31, 2019
Amendment Flag	true
Amendment Description	This Amendment No. 2 on Form 10-K/A (this Amendment) amends the Company's Annual Report on Form 10-K for the year ended December 31, 2019, as amended, (the "Original Filing") and is being filed to show the impact of intangible asset amortization and impairment expense for its Barrett's and Thyroid assets beginning in 2014. Subsequent to the issuance of its consolidated financial statements for the year ended December 31, 2019 and the quarters ended March 31, 2020 and June 30, 2020, the Company determined that amortization should have commenced upon acquisition of those assets as opposed to the Company's previously disclosed policy of beginning asset amortization when the product was launched and generating revenue. The cumulative effect of the additional amortization expense for the periods from August 2014 to December 2019 was an increase to accumulated deficit of approximately $6.0 million to the December 31, 2019 consolidated balance sheet. This Amendment also reflects the impact of an asset impairment charge of its Barrett's asset in the fourth quarter of 2016 of approximately $11.6 million. It has been determined that an impairment charge should have been taken of the Barrett's asset in accordance with the requirements of Accounting Standards Codification (ASC) 360 as of December 31, 2016. A description of these adjustments and a summary showing their effect on the restated consolidated statements of operations for the years 2014- 2017 is provided in Note 1 to the consolidated financial statements. In addition to the errors described above, the restated financial statements also include adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years' financial statements. As a result of the restatement, it was determined that the Company's disclosure controls and procedures were not effective as of December 31, 2019, as referenced in Item 9A. The Company is filing this report in order to amend certain information in Item 1A of Part I, Items 7 and 9A of Part II and Item 15 of Part IV; to reflect the restatement of the 2019 consolidated statements of operations and the notes to the consolidated financial statements attached hereto solely to the extent necessary to reflect the adjustments described herein; and to provide the principal executive officer and principal financial officer certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Except for the foregoing items, no other information in the Original Filing is revised by this Amendment.
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 27,821,137
Entity Common Stock, Shares Outstanding		4,043,673
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,321	$ 6,068
Accounts receivable, net	10,338	9,483
Other current assets	3,851	2,170
Total current assets	16,510	17,721
Property and equipment, net	6,814	837
Other intangible assets, net	15,849	12,538
Goodwill	8,433
Operating lease right of use assets	3,892
Other long-term assets	42	31
Total assets	51,540	31,127
Current liabilities:
Accounts payable	4,709	1,059
Accrued salary and bonus	2,341	1,544
Other accrued expenses	9,476	5,148
Current liabilities from discontinued operations	766	918
Total current liabilities	17,292	8,669
Contingent consideration	2,391	2,693
Operating lease liabilities, net of current portion	2,591
Line of credit	3,000
Other long-term liabilities	4,573	4,319
Total liabilities	29,847	15,681
Commitments and contingencies (Note 12)
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding	26,172
Stockholders' equity:
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 and 2,876,734 shares issued, respectively; 3,920,589 and 2,869,427 shares outstanding, respectively	393	287
Additional paid-in capital	182,514	175,820
Accumulated deficit	(185,665)	(158,981)
Treasury stock, at cost (11,781 and 7,307 shares, respectively)	(1,721)	(1,680)
Total stockholders' equity	(4,479)	15,446
Total liabilities and stockholders' equity	25,368	31,127
Total liabilities, preferred stock and stockholders' equity	$ 51,540	$ 31,127

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	270	270
Preferred stock, shares outstanding	270	270
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,932,370	2,876,734
Common stock, shares outstanding	3,920,589	2,869,427
Treasury stock, shares	11,781	7,307

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended																												12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Sep. 30, 2014		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Income Statement [Abstract]
Revenue, net																													$ 24,220	$ 21,896
Cost of revenue (excluding amortization of $3,989 and $3,589, respectively)																													15,888	10,197
Gross profit																													8,332	11,699
Operating expenses:
Sales and marketing																													11,116	8,421
Research and development																													2,810	2,124
General and administrative																													14,363	8,676
Acquisition related expense																													2,534
Acquisition related amortization expense																													3,989	3,589
Change in fair value of contingent consideration																													(44)	1,522
Total operating expenses																													34,768	24,332
Operating loss																													(26,436)	(12,633)
Accretion expense																													(440)	(331)
Other income (expense), net																													196	263
Loss from continuing operations before tax																													(26,680)	(12,701)
(Benefit) provision for income taxes																													(28)	18
Loss from continuing operations																													(26,652)	(12,719)
Income from discontinued operations, net of tax																													(88)	16
Net loss	$ (10,663)	$ (7,446)	$ (5,304)	$ (3,326)	$ (4,299)	$ (3,126)	$ (2,001)	$ (3,277)	$ (3,400)		$ (6,390)		$ 2,330		$ (8,003)		$ (2,844)		$ (5,296)		$ (5,405)		$ (7,488)		$ (4,614)		$ (4,454)		(26,740)	(12,703)	$ 12,553		$ (22,003)		$ (13,623)		$ (16,768)
Less dividends on preferred stock																													(429)
Net loss attributable to common stockholders																													$ (27,169)	$ (12,703)
Basic and diluted (loss) income per share of common stock:
From continuing operations																													$ (7.23)	$ (4.52)
From discontinued operations																													(0.02)
Net loss per basic and diluted share of common stock									$ (1.54)	[1]	$ (6.61)	[1]	$ 5.32	[1]	$ (43.97)	[1]	$ (15.63)	[1]	$ (29.75)	[1]	$ (34.43)	[1]	$ (49.26)	[1]	$ (30.76)	[1]	$ (29.89)	[1]	$ (7.25)	$ (4.52)	$ (7.96)	[1]	$ (120.90)	[1]	$ (87.95)	[1]	$ (112.53)	[1]
Weighted average number of common shares and common share equivalents outstanding:
Basic																													3,746,000	2,816,000
Diluted																													3,746,000	2,816,000
[1]	Adjusted for reverse stock splits since the filing of the original financial statements.

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Amortization	$ 3,989	$ 3,589

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2014					$ 19,427
Net loss					(4,614)
Balance at Mar. 31, 2015					15,183
Balance at Dec. 31, 2014					19,427
Net loss					(13,623)
Balance at Dec. 31, 2015					10,067
Balance at Mar. 31, 2015					15,183
Net loss					(7,488)
Balance at Jun. 30, 2015					8,347
Net loss					(5,405)
Balance at Sep. 30, 2015					3,400
Balance at Dec. 31, 2015					10,067
Net loss					(5,296)
Balance at Mar. 31, 2016					4,826
Balance at Dec. 31, 2015					10,067
Net loss					(22,003)
Balance at Dec. 31, 2016					(10,111)
Balance at Mar. 31, 2016					4,826
Net loss					(2,844)
Balance at Jun. 30, 2016					2,003
Net loss					(8,003)
Balance at Sep. 30, 2016					(5,979)
Balance at Dec. 31, 2016					(10,111)
Net loss					2,330
Balance at Mar. 31, 2017					7,843
Balance at Dec. 31, 2016					(10,111)
Net loss					12,553
Balance at Dec. 31, 2017	$ 278	$ (1,671)	$ 173,062	$ (148,778)	22,891
Balance, shares at Dec. 31, 2017	2,790,000	6,000
Balance at Dec. 31, 2016					(10,111)
Common stock issued, shares	3,700,000
Balance at Dec. 31, 2019	$ 393	$ (1,721)	182,514	(185,665)	(4,479)
Balance, shares at Dec. 31, 2019	3,932,000	12,000
Balance at Mar. 31, 2017					7,843
Net loss					(6,390)
Balance at Jun. 30, 2017					19,532
Net loss					(3,400)
Balance at Sep. 30, 2017					19,484
Balance at Dec. 31, 2017	$ 278	$ (1,671)	173,062	(148,778)	22,891
Balance, shares at Dec. 31, 2017	2,790,000	6,000
Common stock issued	$ 1				1
Common stock issued, shares	4,000
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Treasury stock purchased		$ (9)			(9)
Treasury stock purchased, shares		1,000
Stock-based compensation expense			597		597
Adoption of ASC 606				2,500	2,500
Adoption of ASC 842
Net loss				(3,277)	(3,277)
Balance at Mar. 31, 2018	$ 279	$ (1,680)	173,659	(149,555)	22,703
Balance, shares at Mar. 31, 2018	2,794,000	7,000
Balance at Dec. 31, 2017	$ 278	$ (1,671)	173,062	(148,778)	22,891
Balance, shares at Dec. 31, 2017	2,790,000	6,000
Net loss					(12,703)
Balance at Dec. 31, 2018	$ 287	$ (1,680)	175,820	(158,981)	15,446
Balance, shares at Dec. 31, 2018	2,877,000	7,000
Balance at Mar. 31, 2018	$ 279	$ (1,680)	173,659	(149,555)	22,703
Balance, shares at Mar. 31, 2018	2,794,000	7,000
Common stock issued	$ 3		282		285
Common stock issued, shares	33,000
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense			419		419
Net loss				(2,001)	(2,001)
Balance at Jun. 30, 2018	$ 282	$ (1,680)	174,360	(151,556)	21,406
Balance, shares at Jun. 30, 2018	2,827,000	7,000
Common stock issued	$ 1		144		143
Common stock issued, shares	10,000
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense			374
Dividends accrued
Net loss				(3,126)	(3,126)
Balance at Sep. 30, 2018	$ 283	$ (1,680)	174,878	(154,682)	18,799
Balance, shares at Sep. 30, 2018	2,837,000	7,000
Common stock issued	$ 4		598		594
Common stock issued, shares	40,000
Common stock issued through market sales, net of expenses
Common stock issued through market sales, net of expenses, shares
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense			344		352
Dividends accrued
Net loss				(4,299)	(4,299)
Balance at Dec. 31, 2018	$ 287	$ (1,680)	175,820	(158,981)	15,446
Balance, shares at Dec. 31, 2018	2,877,000	7,000
Common stock issued	$ 1				1
Common stock issued, shares	9,000
Common stock issued through offering, net of expenses	$ 94		5,868		5,962
Common stock issued through offering, net of expenses, shares	933,000
Treasury stock purchased		$ (32)			(32)
Treasury stock purchased, shares		3,000
Stock-based compensation expense			266		266
Adoption of ASC 606
Adoption of ASC 842				55	55
Net loss				(3,326)	(3,326)
Balance at Mar. 31, 2019	$ 382	$ (1,712)	181,954	(162,252)	18,372
Balance, shares at Mar. 31, 2019	3,819,000	10,000
Balance at Dec. 31, 2018	$ 287	$ (1,680)	175,820	(158,981)	15,446
Balance, shares at Dec. 31, 2018	2,877,000	7,000
Net loss					(26,740)
Balance at Dec. 31, 2019	$ 393	$ (1,721)	182,514	(185,665)	(4,479)
Balance, shares at Dec. 31, 2019	3,932,000	12,000
Balance at Mar. 31, 2019	$ 382	$ (1,712)	181,954	(162,252)	18,372
Balance, shares at Mar. 31, 2019	3,819,000	10,000
Common stock issued	$ 1		72		73
Common stock issued, shares	10,000
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense			205		205
Net loss				(5,304)	(5,304)
Balance at Jun. 30, 2019	$ 383	$ (1,712)	182,231	(167,556)	13,346
Balance, shares at Jun. 30, 2019	3,829,000	10,000
Common stock issued
Common stock issued, shares
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense			205		205
Dividends accrued			(75)		(75)
Net loss				(7,446)	(7,446)
Balance at Sep. 30, 2019	$ 383	$ (1,712)	182,361	(175,002)	6,030
Balance, shares at Sep. 30, 2019	3,829,000	10,000
Common stock issued
Common stock issued, shares	5,000
Common stock issued through market sales, net of expenses	$ 10		218		228
Common stock issued through market sales, net of expenses, shares	98,000
Treasury stock purchased		$ (9)			(9)
Treasury stock purchased, shares		2,000
Stock-based compensation expense			289		289
Dividends accrued			(354)		(354)
Net loss				(10,663)	(10,663)
Balance at Dec. 31, 2019	$ 393	$ (1,721)	$ 182,514	$ (185,665)	$ (4,479)
Balance, shares at Dec. 31, 2019	3,932,000	12,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended																		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities
Net loss	$ (10,663)	$ (7,446)	$ (5,304)	$ (3,326)	$ (4,299)	$ (3,126)	$ (2,001)	$ (3,277)	$ (3,400)	$ (6,390)	$ 2,330	$ (8,003)	$ (2,844)	$ (5,296)	$ (5,405)	$ (7,488)	$ (4,614)	$ (4,454)	$ (26,740)	$ (12,703)	$ 12,553	$ (22,003)	$ (13,623)	$ (16,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization																			4,524	3,801
Interest accretion																			440	331
Bad debt expense																			499
Reversal of DOJ accrual																				(350)
Mark to market on warrants																			(279)	112
Stock-based compensation																			1,535	2,270
Deferred income taxes																			18
Change in estimate on collectability of accounts receivable																			3,479
Change in fair value of contingent consideration																			(44)	1,522
Other gains and expenses, net																			18
Other changes in operating assets and liabilities:
Increase in accounts receivable																			(1,102)	(3,546)
Decrease (increase) in other current assets																			129	(501)
Increase in other long-term assets																			(11)
(Decrease) increase in accounts payable																			(938)	668
Increase in accrued salaries and bonus																			362	150
Decrease in accrued liabilities																			(1,301)	(345)
Increase (decrease) in long-term liabilities																			454	(82)
Net cash used in operating activities																			(18,957)	(8,673)
Cash Flows From Investing Activity
Acquisition of Biopharma, net of cash acquired																			(13,829)
Purchase of property and equipment																			(131)	(449)
Sale of property and equipment																			13
Net cash used in investing activity																			(13,947)	(449)
Cash Flows From Financing Activities
Issuance of common stock, net of expenses																			6,478
Issuance of preferred stock, net of expenses																			25,744
Payment of CGIX note and related interest																			(6,024)
Borrowings on Line of Credit																			3,000
Cash paid for repurchase of restricted shares																			(41)	(9)
Net cash provided by (used in) financing activities																			29,157	(9)
Net decrease in cash and cash equivalents																			(3,747)	(9,131)
Cash and cash equivalents - beginning of year				$ 6,068				$ 15,199											6,068	15,199
Cash and cash equivalents - end of year	$ 2,321				$ 6,068														$ 2,321	$ 6,068	$ 15,199

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	1. Nature of Business and Significant Accounting Policies Nature of Business Interpace Biosciences, Inc. (the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care. Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc. Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has one reporting segment: the Company’s business of developing and selling clinical services and pharma services. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company. Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates. Reverse stock split On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company’s issued and outstanding stock decreased from 39,205,895 to 3,920,589 and 28,694,275 to 2,869,427 at December 31, 2019 and 2018, respectively. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented. Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase. Accounts Receivable, Net The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s diagnostic services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer. Other current assets Other current assets consisted of the following as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Indemnification asset $ - $ 875 Lab supply inventory 1,825 - Prepaid expenses 971 1,230 Funds in escrow 888 - Other 167 65 Total other current assets $ 3,851 $ 2,170 Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven to ten years for furniture and fixtures; two to five years for office and computer equipment; three to seven years for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently four to five years. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations. Software Costs Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three to seven years. Software costs that do not meet capitalization criteria are expensed immediately. External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years. Software costs that do not meet capitalization criteria are expensed immediately. See Note 7, Property and Equipment Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the Consolidated Statements of Operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. Contingencies In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims. Revenue Recognition Beginning January 1, 2018 under ASC 606, the Company began to recognize revenue for billings less contractual allowances and estimated uncollectable amounts for all payer groups on the accrual basis based upon a thorough analysis of historical receipts (see Note 2, Recent Accounting Standards The Company completed its analysis of the ASC 606 impact and incorporated further analysis of first quarter 2018 collections from its commercial payer base in finalizing its ASC 606 adjustments. The impact of recording the cumulative catch-up adjustment under the modified retrospective method was $2.5 million, recorded as an increase to opening retained earnings on January 1, 2018. Prior periods have not been retrospectively adjusted. The Company also finalized its analysis of modified internal controls over financial reporting and the disclosures required starting with Form 10-Q for the first quarter of 2018. Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known. During 2019, the Company recorded a reduction to revenue of $3.5 million due to a change in estimate of the amounts to be collected from 2018 services. For its pharma services, performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Project level fee revenue is recognized ratably over the life of the contract. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. These are for study services and setup management. Deferred revenue from pharma services contracts is recorded at fair value and represents payments received in advance of services rendered. Cost of revenue Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses. Stock-Based Compensation The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and stock appreciation rights (“SARs”). The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. See Note 15, Stock-Based Compensation, Treasury Stock Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital. Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 9, Leases Income taxes Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense. The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense. Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income. Income (Loss) per Share Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2019 and 2018, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive. 1B. Restatement of Previously Issued Consolidated Financial Statements We have restated herein our audited consolidated financial statements as of December 31, 2019 and 2018 and for the years ended December 31, 2019 and December 31, 2018. We have also restated impacted amounts within the accompanying footnotes to the consolidated financial statements which have been noted as such. As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assets upon launch of the test. On December 7, 2020, the Company’s management conferred with the Audit Committee of the Company’s Board of Directors and concluded that (1) a non-cash impairment charge for an intangible asset of approximately $12 million should have been recorded during the Company’s 2016 fiscal year; (2) the Company should have initiated amortization of such intangible asset in fiscal 2014 and therefore each of fiscal years 2014, 2015, 2016, 2017, 2018, and 2019 and the first two quarters of fiscal 2020 require adjustment to record amortization expense; (3) the consolidated financial statements contained in the Company’s Annual Reports on Form 10-K for the years ended December 31, 2014, 2015, 2016, 2017, 2018, and 2019, as well as the consolidated financial statements contained in the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020, should no longer be relied upon. As a result the Company is restating its consolidated financial statements for the years ended December 31, 2019 and December 31, 2018 in this Form 10-K/A. The following tables present reconciliation from our prior periods as previously reported to the restated values for the consolidated balance sheets and the consolidated statement of operations. A description of misstatements is listed below: a) Amortization expense - We recorded amortization expense starting at the dates of acquisition for our Barrett’s and Thyroid intangible assets. The impact of the additional amortization charge was approximately $700 thousand in Fiscal 2014, $2.3 million in Fiscal 2015, $2.0 million in Fiscal 2016, and $340 thousand for each of Fiscal 2017, 2018 and 2019. b) Asset impairment - We recorded an impairment charge on our Barrett’s intangible asset of approximately $11.6 million in the fourth quarter of 2016. c) Adjustments - Adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years’ financial statements. For the Year Ended December 31, 2014 As Asset Asset Other As Total Assets $ 115,906 $ (695 ) $ - $ - $ 115,211 Stockholders’ Equity 20,122 (695 ) - - 19,427 Net Loss $ (16,073 ) $ (695 ) $ - $ - $ (16,768 ) Earnings Per Share* $ (107.87 ) $ (4.66 ) $ - $ - $ (112.53 ) For the Year Ended December 31, 2015 As Asset Asset Other As Total Assets $ 67,712 $ (2,971 ) $ - $ - $ 64,741 Stockholders’ Equity 13,038 (2,971 ) - - 10,067 Net Loss $ (11,356 ) $ (2,276 ) $ - $ - $ (13,632 ) Earnings Per Share* $ (73.26 ) $ (14.68 ) $ - $ - $ (87.95 ) For the Year Ended December 31, 2016 As Asset Asset Other As Total Assets $ 41,778 $ (5,010 ) $ (11,632 ) $ - $ 25,136 Stockholders’ Equity 6,531 (5,010 ) (11,632 ) - (10,111 ) Net Loss $ (8,332 ) $ (2,039 ) $ (11,632 ) $ - $ (22,003 ) Earnings Per Share* $ (45.78 ) $ (11.20 ) $ (63.91 ) $ - $ (120.90 ) For the Year Ended December 31, 2017 As Asset Asset Other As Total Assets $ 53,598 $ (5,347 ) $ (11,632 ) $ - $ 36,619 Stockholders’ Equity 39,869 (5,347 ) (11,632 ) - 22,890 Net Loss $ (12,216 ) $ (337 ) $ - $ - $ (12,553 ) Earnings Per Share* $ (7.75 ) $ (0.21 ) $ - $ - $ (7.96 ) * Adjusted for reverse stock splits since the filing of the original financial statements. INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 2,321 $ - $ 2,321 Accounts receivable, net 10,197 141 (c) 10,338 Other current assets 3,851 - 3,851 Total current assets 16,369 141 16,510 Property and equipment, net 6,814 - 6,814 Other intangible assets, net 33,501 (17,652 ) (a) (b) 15,849 Goodwill 8,433 - 8,433 Operating lease right of use assets 3,892 - 3,892 Other long-term assets 42 - 42 Total assets $ 69,051 $ (17,511 ) $ 51,540 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 4,812 $ (103 ) (c) $ 4,709 Accrued salary and bonus 2,341 - (c) 2,341 Other accrued expenses 9,379 97 (c) 9,476 Current liabilities from discontinued operations 766 - 766 Total current liabilities 17,298 (6 ) 17,292 Contingent consideration 2,391 - 2,391 Operating lease liabilities, net of current portion 2,591 - 2,591 Line of credit 3,000 - 3,000 Other long-term liabilities 4,573 - 4,573 Total liabilities 29,853 (6 ) 29,847 Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding 26,172 - 26,172 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding; 393 - 393 Additional paid-in capital 182,514 - 182,514 Accumulated deficit (168,160 ) (17,505 ) (a) (b) (c) (185,665 ) Treasury stock, at cost (11,781 shares) (1,721 ) - (1,721 ) Total stockholders’ equity 13,026 (17,505 ) (4,479 ) Total liabilities and stockholders’ equity $ 42,879 $ (17,511 ) $ 25,368 Total liabilities, preferred stock and stockholders’ equity $ 69,051 $ (17,511 ) $ 51,540 INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 6,068 $ - $ 6,068 Accounts receivable, net 9,483 - 9,483 Other current assets 2,170 - 2,170 Total current assets 17,721 - 17,721 Property and equipment, net 837 - 837 Other intangible assets, net 29,853 (17,315 ) (a) (b) 12,538 Other long-term assets 31 - 31 Total assets $ 48,442 $ (17,315 ) $ 31,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,059 $ - $ 1,059 Accrued salary and bonus 1,424 120 (c) 1,544 Other accrued expenses 5,091 57 (c) 5,148 Current liabilities from discontinued operations 918 - 918 Total current liabilities 8,492 177 8,669 Contingent consideration 2,693 - 2,693 Other long-term liabilities 4,319 - 4,319 Total liabilities 15,504 177 15,681 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 2,876,734 shares issued and 2,869,427 shares outstanding; 287 - 287 Additional paid-in capital 175,820 - 175,820 Accumulated deficit (141,489 ) (17,492 ) (a) (b) (c) (158,981 ) Treasury stock, at cost (7,307 shares) (1,680 ) - (1,680 ) Total stockholders’ equity 32,938 (17,492 ) 15,446 Total liabilities and stockholders’ equity $ 48,442 $ (17,315 ) $ 31,127 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 24,079 $ 141 (c) $ 24,220 Cost of revenue 15,888 - 15,888 Gross profit 8,191 141 8,332 Operating expenses: Sales and marketing 11,116 - 11,116 Research and development 2,810 - 2,810 General and administrative 14,546 (183 ) (c) 14,363 Acquisition related expense 2,534 - 2,534 Acquisition related amortization expense 3,652 337 (a) 3,989 Change in fair value of contingent consideration (44 ) - (44 ) Total operating expenses 34,614 154 34,768 Operating loss (26,423 ) (13 ) (26,436 ) Accretion expense (440 ) - (440 ) Other income (expense), net 196 - 196 Loss from continuing operations before tax (26,667 ) (13 ) (26,680 ) (Benefit) provision for income taxes (28 ) - (28 ) Loss from continuing operations (26,639 ) (13 ) (26,652 ) Income from discontinued operations, net of tax (88 ) - (88 ) Net loss $ (26,727 ) $ (13 ) $ (26,740 ) Less dividends on preferred stock $ (429 ) $ - $ (429 ) Net loss attributable to common stockholders $ (27,156 ) $ (13 ) $ (27,169 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (7.23 ) $ (0.00 ) $ (7.23 ) From discontinued operations (0.02 ) - (0.02 ) Net loss per basic and diluted share of common stock $ (7.25 ) $ (0.00 ) $ (7.25 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 21,896 $ - $ 21,896 Cost of revenue 10,197 - 10,197 Gross profit 11,699 - 11,699 Operating expenses: Sales and marketing 8,421 - 8,421 Research and development 2,124 - 2,124 General and administrative 8,499 177 (c) 8,676 Acquisition related amortization expense 3,252 337 (a) 3,589 Change in fair value of contingent consideration 1,522 - 1,522 Total operating expenses 23,818 514 24,332 Operating loss (12,119 ) (514 ) (12,633 ) Accretion expense (331 ) - (331 ) Other income (expense), net 263 - 263 Loss from continuing operations before tax (12,187 ) (514 ) (12,701 ) (Benefit) provision for income taxes 18 - 18 Loss from continuing operations (12,205 ) (514 ) (12,719 ) Income from discontinued operations, net of tax 16 - 16 Net loss $ (12,189 ) $ (514 ) $ (12,703 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (4.33 ) $ (0.19 ) $ (4.52 ) From discontinued operations - - - Net loss per basic and diluted share of common stock $ (4.33 ) $ (0.19 ) $ (4.52 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (in thousands) As Previously Reported As Restated For The Year Ended For The Year Ended December 31, 2019 Restatement Amount Restatement Reference December 31, 2019 Shares Amount Shares Amount Common stock: Balance at January 1 2,877 $ 287 $ - 2,877 $ 287 Common stock issued 9 1 - 9 1 Common stock issued through offerings 933 94 - 933 94 Balance at March 31 3,819 382 - 3,819 382 Common stock issued 10 1 - 10 1 Balance at June 30 3,829 383 - 3,829 383 Common stock issued - - - - - Common stock issued through offerings - - - - - Balance at September 30 3,829 383 - 3,829 383 Common stock issued 5 - - 5 - Common stock issued through market sales 98 10 - 98 10 Balance at December 31 3,932 393 - 3,932 393 Treasury stock: Balance at January 1 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased 3 (32 ) - 3 (32 ) Balance at March 31 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at June 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at September 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased 2 (9 ) - 2 (9 ) Balance at December 31 12 (1,721 ) - 12 (1,721 ) Additional paid-in capital: Balance at January 1 175,820 - 175,820 Common stock issued through offerings, net of expenses 5,868 - 5,868 Stock-based compensation expense 266 - 266 Balance at March 31 181,954 - 181,954 Common stock issued 72 - 72 Stock-based compensation expense 205 - 205 Balance at June 30 182,231 - 182,231 Common stock issued through offerings, net of expenses - - - Dividends accrued (75 ) - (75 ) Stock-based compensation expense 2

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Acquisition	2. Acquisition On July 15, 2019, the Company entered into an Asset Purchase Agreement to acquire certain assets and assumed certain liabilities relating to Cancer Genetics, Inc.’s (“CGI”) biopharma business (“BioPharma”) for $23.5 million less certain closing adjustments of $1.98 million (the “Base Purchase Price”). At the closing the Company used the proceeds from an initial tranche of preferred stock financing and paid $13.8 million. Additionally, the Company issued a subordinated seller note to CGI in the amount of $7,692,300. The BioPharma business (presently known as Interpace Pharma Solutions, Inc. or “pharma services”) provides pharmaceutical and biotech companies and non-profit entities performing clinical trials with lab testing services for patient stratification and treatment selection through an extensive suite of molecular and biomarker-based testing services, DNA- and RNA- extraction and customized assay development and trial design consultation. The Base Purchase Price was subject to two additional adjustments following the closing: for the finalized net worth (assets less liabilities) of BioPharma as of June 30, 2019 (the “NWA”), subject to a cap of $775,000, and for certain older accounts receivable, in the aggregate amount of approximately $830,000, still uncollected as of December 31, 2019 (the “ARA”). Any amounts due to the Company under the NWA were to be set off against the Excess Consideration Note and any amounts due to the Company under the ARA were to be either set off against the Excess Consideration Note or, if it is no longer outstanding, satisfied through an AR Holdback (as defined in the Asset Purchase Agreement) mechanism, in each case as further set forth in the Asset Purchase Agreement. Additionally, an indemnification holdback of $735,000 was established as an offset for any potential claims against the Company related to the transaction. The expiration period for the notification of any third-party claims was set at January 15, 2020. On October 18, 2019, a payment of $6,024,489 was made in settlement of the note less remaining holdbacks of $887,858, $735,000 for the Indemnification Holdback and $152,858 for the remaining AR Holdback. As of April 21, 2020, the Company is obligated to pay CGI an additional $735,000 for funds withheld from the Excess Consideration Note to satisfy indemnification obligations under the Asset Purchase Agreement. The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. In connection with the transaction, the Company has preliminarily recorded $8.3 million of goodwill and $7.3 million of finite lived intangible assets. Finite lived intangible assets have a combined weighted-average amortization period of 8.4 years, which consists of ten years for tradenames and eight years for customer relationships. Goodwill results largely from a trained workforce in place and expected synergies from new lines of business. Goodwill recorded in conjunction with the acquisition is deductible for income tax purposes. See Note 8, Goodwill and Other Intangible Assets, The reconciliation of consideration given for BioPharma to the preliminary allocation of the purchase price of assets and liabilities acquired based on their relative fair values is as follows: Cash $ 13,829 Subordinated note payable 6,822 Total consideration $ 20,651 Assets acquired Accounts receivable $ 3,731 Accrued revenue 289 Lab supplies 877 Prepaid expenses 266 Property and equipment 6,412 Operating lease assets 2,187 Acquired identifiable intangible assets: Trademarks and trade name 1,600 Customer relationships 5,700 Total acquired identifiable intangible assets 7,300 Goodwill 8,273 Total assets acquired 29,335 Liabilities assumed Accounts payable (4,535 ) Accrued liabilities (435 ) Deferred revenue (1,076 ) Operating lease liabilities (2,187 ) Finance lease liabilities (451 ) Total liabilities assumed (8,684 ) Net assets acquired $ 20,651 The estimated fair values of assets acquired and liabilities assumed are considered preliminary and are based on the most recent information available. The provisional measurements of fair value set forth above are subject to change. We expect to finalize the valuation as soon as practicable, but no later than one-year from the acquisition date. The following unaudited pro forma consolidated revenues for year ended December 31, 2019 and 2018 assume that the Company had acquired Biopharma Solutions as of January 1, 2018. The pro forma revenues include estimates and assumptions which management believes are reasonable. However, pro forma revenues are not necessarily indicative of the revenues that would have occurred if the acquisition had been consummated as of the date indicated, nor are they necessarily indicative of future revenues. Years Ended December 31, December 31, 2019 2018 Revenue $ 31,722 $ 37,218 The BioPharma business had not historically been accounted for as a separate entity, subsidiary or division of CGI. In addition, stand-alone financial statements related to BioPharma have not been prepared previously as CGI’s financial system was not designed to provide complete financial information of BioPharma. Therefore, the Company was not able to estimate the pro forma impact to net loss or the net loss per share of BioPharma for the years ended December 31, 2019 and 2018.

Recent Accounting Standards

Recent Accounting Standards	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Standards	3. Recent Accounting Standards Recently adopted standards In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which is effective for public companies for annual reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Topic 842 establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. Leases are to be classified as either finance or operating leases, with such classification affecting the pattern or expense recognition in the statement of operations. We adopted this new standard as of January 1, 2019, by using the alternative modified transition method. See Note 9, Leases Standards not yet effective In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment, which removes the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted and applied prospectively. Management is evaluating ASU 2017-04 to determine the impact on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. This ASU is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance of this ASU is effective. Based upon the level and makeup of our financial asset portfolio, past loan loss activity and current known activity regarding our outstanding loans, we do not expect that this ASU will have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (ASU 2017-04). ASU 2017-04 eliminates step two from the goodwill impairment test, thereby eliminating the requirement to calculate the implied fair value of a reporting unit. ASU 2017-04 will require us to perform our annual goodwill impairment test by comparing the fair value of our reporting units to the carrying value of those units. If the carrying value exceeds the fair value, we will be required to recognize an impairment charge; however, the impairment charge should not exceed the amount of goodwill allocated to such reporting unit. ASU 2017-04 is required to be implemented on a prospective basis for fiscal years beginning after December 15, 2019. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	4. Liquidity As of December 31, 2019, the Company had cash and cash equivalents of $2.3 million, net accounts receivable of $10.3 million, total current assets of $16.5 million and total current liabilities of $17.3 million. For the year ended December 31, 2019, the Company had a net loss of $26.7 million and cash used in operating activities was $19.0 million. We do not expect to generate positive cash flows from operations for the year ending December 31, 2020. We intend to meet our ongoing capital needs by using our available cash, proceeds under the Securities Purchase and Exchange Agreement, additional borrowings under the Line of Credit as well as increasing our line of credit limit by an additional $4 million as a result of the additional accounts receivable acquired in July 2019 as part of our acquisition of pharma services (which requires a modification to the bank agreement and approval by SVB, as well as approval by our preferred shareholders), revenue growth and margin improvement, collecting accounts receivable, containing costs as well as exploring other financing options. Management believes that the Company has sufficient cash on hand and available to sustain operations through at least April 23, 2021. However, there is no guarantee that additional capital can be raised to fund our future operations. In September 2019, we entered into the Equity Distribution Agreement (the “Agreement”) with Oppenheimer & Co. Inc., as sales agent (the “Agent”), pursuant to which we may, from time to time, issue and sell shares of our common stock in an aggregate offering price of up to $4.8 million through the Agent. See Note 13, Equity, In January 2020, we sold 20,000 preferred shares to investors, led by 1315 Capital, for net proceeds of approximately $19.5 million. See Note 21, Subsequent Events, In November 2018, the Company entered into up to a $4.0 million secured Line of Credit facility including a 3-year term loan for $850,000 with Silicon Valley Bank (“SVB”). The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company’s eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months. Term loan outstanding amounts incur interest at a rate per annum equal to the greater of the Wall Street Journal Prime Rate (the “Prime Rate”) and 5.00%. Revolving Line outstanding amounts incur interest at a rate per annum equal to the Prime Rate plus 0.5%. As of December 31, 2019, $3.0 million was outstanding. See Note 21, Subsequent Events During April 2020, the Company applied for various federal stimulus loans, grants and advances made available under Title 1 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, including an approximate $3.5 million loan request under the Small Business Administration (SBA) Paycheck Protection Program (PPP), an approximate $0.65 million grant from the Department of Health and Human Services (HSS), and approximately $2.1 million in advances under the Centers for Medicare & Medicaid Services (CMS) accelerated and advance payment program. Each of these loans, grants and advances require certain certifications by the Company and impose specific limitations on the use of the proceeds. As of April 21, 2020, we received $2.1 million in advances under the CMS accelerated and advance payment program, as well as the $0.65 million HSS grant. The CMS advance will be offset against future Medicare billings of the Company, and the HSS grant is subject to certain conditions regarding its use, including developing coronavirus and serology tests. There is no guarantee that any other loans, grants or advances will be approved. As of April 21, 2020, the Company’s PPP loan has not yet been approved, pending new legislation increasing the pool. The PPP provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. If the Company is successful in obtaining a PPP loan, we intend to use the proceeds for purposes consistent with the PPP and expect to meet the conditions for forgiveness of the loan. As of April 21, 2020 we have approximately $18.4 million of cash on hand. Also as of April 21, 2020, the Company has no further availability on its credit facility, but is in the process of completing an agreement with SVB to expand the credit facility from $4.0 million to $8.0 million. No assurance can be given that such an expansion agreement will be entered into.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	5. Discontinued Operations The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2019 and December 31, 2018: December 31, 2019 December 31, 2018 Accounts payable $ - $ 192 Accrued liabilities 766 726 Current liabilities from discontinued operations 766 918 Total liabilities $ 766 $ 918 Company management is currently winding down certain legal entities which are no longer active within its corporate structure, none of which falls under the criteria of discontinued operations. However, this activity may result in the restructuring of past liabilities, which may result in further reductions based upon new estimates and third-party evaluations.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations for assets and liabilities include certain unobservable inputs in the assumptions and projections used in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below. As of December 31, 2019 Fair Value Measurements Carrying Fair As of December 31, 2019 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,893 $ 2,893 $ - $ - $ 2,893 Other long-term liabilities: Warrant liability (2) 82 82 - - 82 $ 2,975 $ 2,975 $ - $ - $ 2,975 As of December 31, 2018 Fair Value Measurements Carrying Fair As of December 31, 2018 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen $ 3,127 $ 3,127 $ - $ - $ 3,127 Other long-term liabilities: Warrant liability 361 361 - - 361 $ 3,488 $ 3,488 $ - $ - $ 3,488 In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. Cancellation Adjustment of Obligation/ to Fair Value/ December 31, 2018 Payments Accretion Conversions Exercises Mark to Market December 31, 2019 Asuragen $ 3,127 $ (630 ) $ 440 $ - $ (44 ) $ 2,893 Underwriters Warrants 361 - - - (279 ) 82 $ 3,488 $ (630 ) $ 440 $ - $ (323 ) $ 2,975 Certain of the Company’s non-financial assets, such as other intangible assets are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	7. Property and Equipment Property and equipment consisted of the following as of December 31, 2019 and 2018: December 31, 2019 2018 Furniture and fixtures $ 242 $ 62 Lab and office equipment 6,353 1,686 Computer equipment 339 172 Internal-use software 1,276 113 Leasehold improvements 506 175 Property and equipment 8,716 2,208 Less accumulated depreciation and amortization (1,902 ) (1,371 ) Net property and equipment $ 6,814 $ 837 Depreciation and amortization expense from continuing operations was approximately $0.5 million and $0.2 million for the years ended December 31, 2019 and 2018, respectively. There was internal-use software amortization expense included in depreciation and amortization expense in 2019 of approximately six thousand. As of December 31, 2019, capitalized external-use software was fully amortized.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	8. Goodwill and Other Intangible Assets Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at December 31, 2019 was $8.4 million. The net carrying value of the identifiable intangible assets as of December 31, 2019 and December 31, 2018 is as follows: As Restated As Restated As of December 31, 2019 As of December 31, 2018 Life Carrying Carrying (Years) Amount Amount Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,719 6,719 BioPharma acquisition: Trademarks 10 1,600 - Customer relationships 8 5,700 - CLIA Lab 2.3 $ 609 $ 609 Total $ 39,288 $ 31,988 Accumulated Amortization $ (23,439 ) $ (19,450 ) Net Carrying Value $ 15,849 $ 12,538 The following table displays a roll forward of the carrying amount of goodwill from January 1, 2018 to December 31, 2019: Carrying Amount Balance as of January 1, 2018 $ - Balance as of December 31, 2018 - Goodwill acquired 8,273 Adjustments 160 Balance as of December 31, 2019 $ 8,433 Amortization expense was approximately $4.0 million and $3.6 million for the years ended December 31, 2019 and 2018, respectively. Estimated amortization expense for the next five years is as follows: As Restated 2020 2021 2022 2023 2024 $ 4,871 $ 4,078 $ 2,156 $ 1,745 $ 873

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	9. Leases In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which establishes a ROU model that requires a lessee to record a ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. Effective January 1, 2019, the Company adopted the provisions of Topic 842 using the alternative modified transition method, with a cumulative effect adjustment to the opening balance of accumulated deficit on the date of adoption, and prior periods not restated, as allowed under the provisions of Topic 842. The Company also elected to use the practical expedients permitted under the transition guidance of Topic 842, which provides for the following: the carryforward of the Company’s historical lease classification, no requirement for reassessment of whether an expired or existing contract contains an embedded lease, no reassessment of initial direct costs for any leases that exist prior to the adoption of the new standard, and the election to consolidate lease and non-lease components. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet. The Company recorded $2.4 million of right-of-use lease assets and $2.5 million of lease liabilities upon adoption, primarily relating to rentals of space for our corporate headquarters and laboratories, as well as equipment leases, all under operating leases. In addition, the Company recorded a cumulative adjustment to opening accumulated deficit of $0.1 million. With the acquisition of the Biopharma business of CGI in 2019, the Company added $2.2 million of operating lease assets and liabilities and $0.5 million of finance lease assets and liabilities to its balance sheet. Finance lease assets are included in fixed assets, net of accumulated depreciation. The table below presents the lease-related assets and liabilities recorded in the Consolidated Balance Sheet: Classification on the Balance Sheet December 31, 2019 Assets Financing lease assets Property and equipment, net $ 998 Operating lease assets Operating lease right of use assets 3,892 Total lease assets $ 4,890 Liabilities Current Financing lease liabilities Other accrued expenses $ 184 Operating lease liabilities Other accrued expenses 1,321 Total current lease liabilities $ 1,505 Noncurrent Financing lease liabilities Other long-term liabilities 123 Operating lease liabilities Operating lease liabilities, net of current portion 2,591 Total long-term lease liabilities 2,714 Total lease liabilities $ 4,219 The weighted average remaining lease term for the Company’s operating leases was 2.7 years as of December 31, 2019 and the weighted average discount rate for those leases was 6.0%. The Company’s operating lease expenses are recorded within cost of revenue and general and administrative expenses. The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2019: Operating Leases Financing Leases 2020 1,472 226 2021 1,295 120 2022 1,223 13 2023 344 - Total minimum lease payments 4,334 359 Less: amount of lease payments representing effects of discounting 418 52 Present value of future minimum lease payments 3,916 307 Less: current obligations under leases 1,321 184 Long-term lease obligations $ 2,595 $ 123

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Retirement Plans	10. Retirement Plans The Company offers an employee 401(k) saving plan. Under the Interpace Biosciences, Inc. 401(k) Plan, employees may contribute up to 50% of their pre- or post-tax base compensation. The Company currently offers a safe harbor matching contribution equal to 100% of the first 3% of the participant’s contributed base salary plus 50% of the participant’s base salary contributed exceeding 3% but not more than 5%. Participants are not allowed to invest any of their 401(k) funds in the Company’s common stock. The Company’s total contribution expense from continuing operations related to the 401(k) plan for the years ended December 31, 2019 and December 31, 2018 was approximately $0.3 million and $0.2 million, respectively.

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	11. Accrued Expenses and Other Long-Term Liabilities Other accrued expenses consisted of the following as of December 31, 2019 and 2018: As Restated As Restated December 31, 2019 December 31, 2018 Accrued royalties $ 1,934 $ 1,399 Indemnification liability - 875 Contingent consideration 502 434 Operating lease liability 1,321 - Financing lease liability 184 - Deferred revenue 457 - Payable to CGI 888 - Accrued sales and marketing - diagnostics 197 - Accrued lab costs - diagnostics 163 150 Accrued professional fees 1,399 758 Taxes payable 403 285 Unclaimed property 565 565 All others 1,463 682 Total other accrued expenses $ 9,476 $ 5,148 Other long-term liabilities consisted of the following as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Warrant liability $ 82 $ 361 Uncertain tax positions 4,081 3,838 Deferred revenue 269 - Other 141 120 Total other long-term liabilities $ 4,573 $ 4,319

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies The Company leases facilities and certain equipment under agreements classified as operating leases, which expire at various dates through June 2023. Substantially all of the property leases provide for increases based upon use of utilities and landlord’s operating expenses as well as pre-defined rent escalations. Total expense from continuing operations under these agreements for the years ended December 31, 2019 and 2018 was approximately $1.3 million and $0.7 million, respectively. As of December 31, 2019, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows: Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 4,334 $ 1,472 $ 2,518 $ 344 $ - Total $ 4,334 $ 1,472 $ 2,518 $ 344 $ - Litigation Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

Equity

Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Equity	13. Equity Public Offering On January 25, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) with respect to the issuance and sale of an aggregate of 933,334 shares (the “Firm Shares”) of the Company’s common stock in an underwritten public offering. Pursuant to the Underwriting Agreement, the Company also granted Wainwright an option, exercisable for 30 days, to purchase an additional 140,000 shares of common stock. The option expired unexercised. The Firm Shares were offered to the public at a price of $7.50 per Share. Wainwright purchased the Firm Shares from the Company pursuant to the Underwriting Agreement at an effective price of $6.975 per share. The share and per share numbers discussed above have been adjusted for the reverse stock split which took place in January 2020. The Company received net proceeds, after deducting underwriter discounts and commissions and other expenses related to the offering, in the amount of approximately $5.9 million. The Company used the net proceeds from the offering for working capital, capital expenditures, business development and research and development expenditures, and the acquisition (in part) of Biopharma Business. Preferred Stock Issuance The Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) on July 15, 2019 with Ampersand 2018 Limited Partnership (the “Investor”), a fund managed by Ampersand Capital Partners, providing for the issuance and sale to the Investor of up to an aggregate of $27.0 million in convertible preferred stock, par value $0.01 per share, of the Company consisting of two series, Series A (“Series A”) and Series A-1 (“Series A-1” and together with the Series A, the “Preferred Stock”), both at an issuance price per share of 100 thousand (the “Stated Value”), to be funded at up to two different closings (the “Investment”). The initial closing, which was consummated promptly after the execution of the Securities Purchase Agreement, involved the issuance of 60 newly created shares of Series A at an aggregate purchase price of $6.0 million, and 80 newly created shares of Series A-1 at an aggregate purchase price of $8.0 million, for net proceeds of approximately $13.1 million. The Securities Purchase Agreement contemplated a second closing (the “Second Closing”), which would only be effected following the fulfillment to the Investor’s satisfaction of customary conditions, including, among others, the approval by the stockholders of the Company, as required under the rules of the Nasdaq Stock Market LLC (the “Nasdaq Listing Rules”), of the issuance of shares of common stock upon conversion of the Preferred Stock in excess of the aggregate number of shares of common stock that the Company may issue upon conversion of the Preferred Stock without breaching its obligations under the Nasdaq Listing Rules (the “Stockholder Approval”). The terms of the Series A-1 provided that each share of Series A-1 would automatically convert into one share of Series A upon the Company obtaining the Stockholder Approval. See Note 21, Subsequent Events, Stockholder Approval was obtained on October 10, 2019 for the Securities Purchase Agreement discussed above and each share of Series A-1 issued to the Investor at the initial closing automatically converted into one share of Series A on that day. On October 16, 2019, the Company and the Investor consummated the Second Closing. At the Second Closing, the Company issued to the Investor 130 newly created shares of Series A at an aggregate gross purchase price of $13.0 million. The Company used the proceeds from the Second Closing to make the maturity date payment, subject to certain holdbacks, with respect to the promissory note issued by a subsidiary of the Company to CGI, and expects to use the remaining proceeds for general corporate purposes, including the integration of the BioPharma Business. The Company issued the aforementioned note in connection with the acquisition of its BioPharma Business. The Series A was offered and sold pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. The shares to be issued upon conversion of the Series A have not been registered under the Securities Act and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements. As of December 31, 2019 and 2018, there were 270 and zero issued and outstanding shares of preferred stock, respectively. ATM program On September 20, 2019, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Oppenheimer & Co. Inc., as sales agent (the “Agent”), pursuant to which the Company may, from time to time, issue and sell shares of its Common Stock, at an aggregate offering price of up to $4.8 million (the “Shares”) through the Agent. Under the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, as amended. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0% of the aggregate gross proceeds from the Shares sold. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. As of December 31, 2019, 97,817 shares (as adjusted for the reverse stock split) have been sold for net proceeds to the Company of approximately $0.2 million. As a result of the January 15, 2020 Investment and Exchange, additional Shares may no longer be sold under the ATM arrangement without a majority approval by the holders of the Series B Preferred Stock in accordance with the Amended and Restated Investor Rights Agreement entered into on that date

Warrants

Warrants	12 Months Ended
	Dec. 31, 2019
Warrants
Warrants	14. Warrants Warrants outstanding and warrant activity for the year ended December 31, 2019 are as follows: Description Classification Exercise Price Expiration Date Warrants Issued Warrants Exercised Warrants Cancelled/ Expired Balance Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 - - 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 - - 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 - (4,000 ) 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 (567,286 ) - 870,214 870,214 Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 - - 15,000 15,000 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 - - 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 - - - 65,434 1,990,934 (567,286 ) (4,000 ) 1,354,214 1,419,648

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	15. Stock-Based Compensation The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, stock appreciation rights (“SARs”) and restricted shares from the Interpace Biosciences, Inc. 2019 Equity Incentive Plan. No new grants may be made under the Company’s prior stock incentive plan, the Interpace Diagnostics Group, Inc. (now known as Interpace Biosciences, Inc.) Amended and Restated 2004 Stock Award and Incentive Plan (the “2004 Plan”). Unless earlier terminated by action of the Company’s board of directors, the 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the 2004 Plan with respect to outstanding awards thereunder. Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The Company granted stock options in 2017 which vest monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and SARs. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Company’s expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility is based on historical volatility. As there is no trading volume for the Company’s options, implied volatility is not representative of the Company’s current volatility so the historical volatility of the Company’s common stock is determined to be more indicative of the Company’s expected future stock performance. The expected life is determined using the safe-harbor method. The Company expects to use this simplified method for valuing employee options and SARs grants until more detailed information about exercise behavior becomes available over time. The Company bases the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options or SARs. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The Company recognizes compensation cost, net of estimated forfeitures, arising from the issuance of stock options and SARs on a straight-line basis over the vesting period of the grant. In October 2019, the Company’s employee stock purchase plan was approved by shareholders. This plan will be implemented in 2020. The estimated compensation cost associated with the granting of restricted stock and restricted stock units is based on the fair value of the Company’s common stock on the date of grant. The Company recognizes the compensation cost, net of estimated forfeitures, arising from the issuance of restricted stock and restricted stock units on a straight-line basis over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. The share and per share numbers in the following tables have been adjusted for the reverse stock split which took place in January 2020. The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2019 and December 31, 2018. December 31, 2019 December 31, 2018 Risk-free interest rate 2.34 % 2.71 % Expected life 5.9 years 6.0 years Expected volatility 128.58 % 127.18 % Dividend yield - - The weighted-average fair value of stock options granted during the year ended December 31, 2019 was estimated to be $8.50. The weighted-average fair value of stock options granted during the year ended December 31, 2018 was estimated to be $9.30. There were no options or SARs exercised in 2019 or 2018. Historically, shares issued upon the exercise of options have been new shares and have not come from treasury shares. The impact of RSUs and stock options on net loss for the years ended December 31, 2019 and 2018 is as follows: 2019 2018 RSUs $ 243 $ 301 Options 722 1,433 Total stock-based compensation expense $ 965 $ 1,734 A summary of stock option and SARs activity for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Price Weighted-Average Remaining Contractual Period (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 288,950 $ 21.40 8.83 $ - Granted 132,545 9.50 9.30 - Exercised - Forfeited or expired (5,817 ) 387.10 - Outstanding at December 31, 2019 415,678 12.50 8.45 - Exercisable at December 31, 2019 202,206 15.20 7.91 - Vested and expected to vest 402,921 12.60 8.43 - A summary of the status of the Company’s non-vested options for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Date Fair Value Non-vested at January 1, 2019 134,089 $ 9.30 Granted 132,545 8.50 Vested (53,150 ) 9.00 Forfeited - - Non-vested at December 31, 2019 213,484 $ 8.80 The aggregate fair value of SARs and options vested during the years ended December 31, 2019 and 2018 was $0.5 million and $1.2 million, respectively. The weighted-average grant date fair value of options vested during the year ended December 31, 2018 was $1.40. A summary of the Company’s non-vested shares of restricted stock units for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Date Fair Value Average Remaining Vesting Period (in years) Aggregate Intrinsic Value Non-vested at January 1, 2019 36,224 $ 11.70 1.37 $ 289,758 Granted 27,637 9.80 - - Vested (14,486 ) 13.70 - - Forfeited - - - - Non-vested at December 31, 2019 49,375 $ 10.00 1.11 $ 246,875 The aggregate fair value of restricted stock units vested during each of the years ended December 31, 2019 and 2018 was $0.2 million and $0.1 million, respectively. As of December 31, 2019, there was approximately $1.6 million of total unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock units.

Revenue Sources

Revenue Sources	12 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Revenue Sources	16. Revenue Sources The Company’s clinical services customers consist primarily of physicians, hospitals and clinics. Its revenue channels include Medicare, Medicare Advantage, Medicaid, Client Billings (hospitals, etc.), and commercial payers. The following sets forth the net revenue generated by revenue channel accounted for more than 10% of the Company’s revenue from continuing operations during the years ended December 31, 2019 and 2018, respectively. For the years ended December 31, 2019 and December 31, 2018, revenue from Medicare was approximately 44% and 41% of total revenue, respectively. Years Ended December 31, Customer 2019 2018 Medicare $ 10,605 $ 9,114 Commercial Payors $ 7,589 $ 4,079 Client Billings $ 3,521 $ 3,621 Medicare Advantage $ 1,912 $ 3,011

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes The benefit from income taxes on continuing operations for the years ended December 31, 2019 and 2018 is comprised of the following: 2019 2018 Current: Federal $ (46 ) $ (2 ) State - 20 Total current (46 ) 18 Deferred: Federal 11 - State 7 - Total deferred 18 - Benefit from income taxes $ (28 ) $ 18 The Company performs an analysis each year to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. The Company’s recent operating results and projections of future income weighed heavily in the Company’s overall assessment. As a result of this analysis, the Company continues to maintain a full valuation allowance against its federal and state net deferred tax assets at December 31, 2019 as the Company believes that it is more likely than not that these assets will not be realized. In the current year, the company maintains a full valuation allowance in consolidation and no separate company deferred tax liability recorded will be recorded. The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2019 and 2018 are as follows: As Restated As Restated 2019 2018 Deferred tax assets: Federal net operating loss carryforwards $ 44,152 $ 40,158 State net operating loss carryforwards 5,687 4,541 Compensation 1,399 1,100 Allowances and reserves 457 1,007 State taxes 848 794 Credit carryforward 229 234 163(j) interest 141 - Leases 23 - Deferred revenue 88 89 Property, plant and equipment - 16 53,024 47,939 Deferred tax liability: Intangible assets 1,112 (44 ) Property, plant and equipment (263 ) - Valuation allowance (53,891 ) (47,895 ) Deferred tax liability-net valuation allowance $ (18 ) $ - The Company’s deferred tax asset and deferred tax liabilities are included within Other long-term liabilities The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. During December 2016 through December 2019, the Company issued approximately 3.7 million shares of common stock, and for its preferred share issuances, another 3.47 million shares on an as-converted basis. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. This would limit the amount of NOLs that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. We are currently evaluating the ownership history of our company to determine if there were any ownership changes as defined under Section 382(g) of the Code and the effects any ownership change may have had. A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows: 2019 2018 Federal statutory rate 21.0 % 21.0 % State income tax rate, net of Federal tax benefit 3.0 % 2.9 % Meals and entertainment (0.2 )% (0.3 )% Contingent consideration 0.0 % 0.0 % Tax reform change 0.0 % 0.0 % Valuation allowance (23.8 )% (23.7 )% Other non-deductible 0.0 % (0.1 )% Naked credit (0.1 )% 0.0 % Discontinued operations allocation 0.2 % 0.0 % Effective tax rate 0.1 % (0.2 )% The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2019: Unrecognized Tax Benefits Balance of unrecognized benefits as of January 1, 2018 $ 1,117 Reductions for tax positions of prior years (323 ) Balance as of December 31, 2018 $ 794 Additions for tax positions of prior years 54 Balance as of December 31, 2019 $ 848 As of December 31, 2019 and 2018, the total amount of gross unrecognized tax benefits was $0.8 million and $0.8 million, respectively. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of December 31, 2019 and 2018 was $0.8 million and $0.8 million, respectively. The Company recognized interest and penalties of $0.3 million and $0.2 million, respectively, related to uncertain tax positions in income tax expense during each of the years ended December 31, 2019 and 2018. At December 31, 2019 and 2018, accrued interest and penalties, net were $3.3 million and $3.0 million, respectively, and included in the Other long-term liabilities Management plans to commence filing tax clearance certificates in states and related tax jurisdictions in which un-recognized tax benefits attributable to its former operating entities are recorded as long-term liabilities on the accompanying balance sheet. This process can range from 6 to 18 months before the Company receives clearance as to balances, if any, it may owe to a particular state or tax jurisdiction. Upon receipt and acknowledgment from a state or tax jurisdiction, the Company will settle the remaining obligation or reverse the recorded amount owed during the period in which the tax clearance certificate is obtained. The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2019: Jurisdiction Tax Years Federal 2015 - 2019 State and Local 2014 - 2019 To the extent there was a failure to file a tax return in a previous year; the statute of limitation will not begin until the return is filed. There were no examinations in process by the Internal Revenue Service as of December 31, 2019. In 2014, the Company was selected for examination by the Internal Revenue Service for the tax periods ending December 31, 2012 and December 31, 2011 that concluded in 2016 with no adjustments. The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017 and became effective for tax years beginning after December 31, 2017. The TCJA had significant changes to U.S. tax law, lowering U.S. corporate income tax rates, implementing a territorial tax system, imposing a one-time transition tax on deemed repatriated earnings of foreign subsidiaries and modified the taxation of other income and expense items. The TCJA reduces the U.S. corporate income tax rate from 34% to 21%, effective January 1, 2018. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 34% to 21% under the TCJA, we revalued deferred tax assets, net as of December 31, 2017. The tax impact of revaluation of the deferred tax assets, net was $22,768,303, which was wholly offset by a corresponding reduction in our valuation allowance of $22,768,303 resulting in a no net impact to our income tax expense. Due to the timing of the new tax law and the substantial changes it brings, the staff of the Securities and Exchange Commission (the “SEC”) issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides registrants a measurement period to report the impact of the new US tax law. During the measurement period, provisional amounts for the effects of the law are recorded to the extent a reasonable estimate can be made. To the extent that all information necessary is not available, prepared or analyzed, companies may recognize provisional estimated amounts for a period of up to one year following enactment of the TCJA. The Company did not have any changes to provisional estimates.

Historical Basic and Diluted Ne

Historical Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Historical Basic and Diluted Net Loss Per Share	18. Historical Basic and Diluted Net Loss per Share A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018 is as follows (rounded to thousands): Years Ended December 31, 2019 2018 Basic weighted average number of common shares 3,746 2,815 Potential dilutive effect of stock-based awards - - Diluted weighted average number of common shares 3,746 2,815 The Company’s Preferred Stock, on an as converted basis, and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands): Years Ended December 31, 2019 2018 Options 416 283 Stock-settled stock appreciation rights (SARs) - 6 Restricted stock units (RSUs) 49 36 Warrants 1,420 1,354 1,885 1,679

Line of Credit

Line of Credit	12 Months Ended
	Dec. 31, 2019
Line of Credit Facility [Abstract]
Line of Credit	19. Line of Credit On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provides for up to $4.0 million of debt financing consisting of a term loan of up to $850,000 and a revolving line of credit based on its outstanding accounts receivable (the “Revolving Line”) of up to $3.75 million. The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company’s eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021. As of December 31, 2019, the Company had drawn $3.0 million of the available funds with the Revolving Line and had $750,000 of remaining availability as $250,000 of the Line of Credit is used to secure the issuance of a standby letter of credit by SVB. See also Note 21, Subsequent Events – Revolving line of credit. As of December 31, 2019, we were in violation of a financial covenant for which we received a waiver from SVB on March 19, 2020. Since February 29, 2020 we were in compliance with all covenants.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	20. Supplemental Cash Flow Information For The Years Ended December 31, 2019 2018 Net cash used in operating activities of discontinued operations $ (30 ) $ (361 ) Net cash provided by investing activities of discontinued operations $ - $ - Supplemental Disclosure of Other Cash Flow Information (in thousands) Cash paid for taxes $ 227 $ 324 Cash paid for interest $ 170 $ - Supplemental Disclosures of Non Cash Activities (in thousands) Years Ended December 31, 2019 2018 Operating Adoption of ASC 606 $ - $ 2,500 Prepaid stock grants issued to vendors $ - $ 497 Adoption of ASC 842 - right of use asset $ 2,449 $ - Adoption of ASC 842 - operating lease liability $ 2,536 $ - Financing Accrued financing costs $ 342 $ - Accrued preferred dividends $ 429 $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events Impact of COVID-19 pandemic We have taken what we believe are all necessary precautions to safeguard our employees from the Coronavirus (COVID-19) pandemic. We are following CDC guidance and local restrictions. All employees who do not work in a lab are currently on a telecommunication work arrangement. Our employees in the lab are wearing what we believe is appropriate protective gear. If an employee tests positive, then we will take necessary and available precautions in the lab to reduce the potential spread of COVID-19, including decontamination and temporary lab closures. There can be no assurance that key employees will not become ill or that we will able to continue to operate our labs. We have furloughed a significant number of employees as a result of reductions in customer demand and we have closed our administrative offices. Our management, finance staff and sales personnel have generally been able to successfully work remotely. Our labs require in-person staffing and as of the date of this report, we have been able to successfully operate our labs though a combination of social distancing and protective equipment. The extent to which the COVID-19 pandemic impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the outbreak and the actions taken to contain or treat the coronavirus outbreak. In particular, the continued spread of the coronavirus globally is adversely affecting global economies and financial markets resulting in an economic downturn which could materially and adversely impact our operations including, without limitation, the functioning of our laboratories, the availability of supplies including reagents, the progress and data collection of our pharma services, customer demand and travel and employee health and availability. We believe that the COVID-19 pandemic will adversely impact our results of operations, cash flows and financial condition for the first and second quarters of fiscal 2020 and possibly beyond. Our fiscal 2020 first quarter revenue has been impacted by lower than expected clinical service volume throughout March 2020. We believe this has resulted from the temporary reduction in non-essential testing procedures in connection with the COVID-19 pandemic. While we experienced a substantial increase in clinical services revenue compared to the first quarter of 2019, our March 2020 test volume decreased substantially compared to our February 2020 volume. Our pharma services preliminary first quarter revenue increased throughout the first quarter and average daily accessions improved in March 2020 as compared to January and February 2020. We continue to monitor the rapidly evolving situation and guidance from authorities, including federal, state and local public health authorities and may take additional actions based on their recommendations. In these dynamic circumstances, there may be developments outside our control requiring us to adjust our operating plan. Currently volume of testing in our clinical services labs has slowed, as noted above, and we believe we have taken the necessary actions to support the lower volume. Our pharma services customers have indicated that there could be a slowdown in clinical trials but thus far volume has not suffered. All of our labs are currently operating and we believe we are appropriately staffed for the volume of work. At this time, we do not anticipate any lab closures beyond temporary work stoppages from time to time to clean and disinfect the labs. To date, we have not lost any of our customer base and we are not aware of any customers with potential bankruptcy or payment issues. Lab supplies including reagents have been secured to mitigate any potential supply chain issues for the foreseeable future and we are not observing any shortages due to supply chain issues. Our third party clinical services billing and collections company has taken steps to continue operations remotely. There have been indications that payer processing may slow down but so far there has been little or no material impact to our collections . As of April 21, 2020 we have approximately $18.4 million of cash on hand which includes $3.4 million drawn on our credit facility, $2.1 million in advances received under the Centers for Medicare & Medicaid Services (CMS) accelerated and advance payment program, and $0.65 million in the form of a grant received from the Department of Health and Human Services, which is subject to certain conditions regarding its use, including developing coronavirus and serology tests. Also as of April 21, 2020, the Company has maximized its borrowing under its line of credit facility and therefore has no further availability on its credit facility; however, we are in the process of seeking to expand availability under the credit facility from $4.0 to $8.0 million on terms similar to existing terms, but there can be no assurance that such credit line extension will be granted or that it will be granted on commercially reasonable and acceptable terms. As of the date of this report, the Company believes it will be able to access additional financing though commercial bank loans and the sale of its securities, although there can no assurance that financing market conditions will not change or that such financing can be obtained. It is anticipated that if business conditions remain at these lower levels for clinical services customers and our pharma services customers similarly reduce their demand until the end of July and thereafter demand recovers to pre COVID-19 pandemic levels, then we believe we will have ample resources to continue to service our customers. However, should business conditions deteriorate further or last longer than anticipated, then our business may be materially and adversely affected. The Company’s leadership team is monitoring the situation on a daily basis and is has developed contingency plans to potentially mitigate the anticipated adverse financial impact of the COVID-19 pandemic. These contingency plans include significant cost saving actions to offset any volume shortfall and additional action plans to react to further potential declines. As of April 2020, we are in the process of launching a new product line of antibody testing for the COVID-19 virus. We are currently validating a serological test that detects antibodies specific to the virus. However, there is no guarantee that we will be successful or realize any revenue or benefit from these efforts. ATM program In January 2020, under the Agreement with the Agent, the Company sold 80,341 (as adjusted for the reverse stock split) shares of common stock for approximate net proceeds to the Company of $0.5 million. Reverse stock split On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. Our common stock began trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on January 15, 2020. There was no change in its ticker symbol as a result of the Reverse Stock Split. Federal Stimulus Programs in Connection with Coronavirus Pandemic During April 2020, the Company applied for various federal stimulus loans, grants and advances made available under Title 1 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, including an approximate $3.5 million loan request under the Small Business Administration (SBA) Paycheck Protection Program (PPP), an approximate $0.65 million grant from the Department of Health and Human Services (HSS), and approximately $2.1 million in advances under the Centers for Medicare & Medicaid Services (CMS) accelerated and advance payment program. Each of these loans, grants and advances require certain certifications by the Company and impose specific limitations on the use of the proceeds. As of April 21, 2020, we received $2.1 million in advances under the CMS accelerated and advance payment program, as well as the $0.65 million HSS grant. The CMS advance will be offset against future Medicare billings of the Company, and the HSS grant is subject to certain conditions regarding its use, including developing coronavirus and serology tests. There is no guarantee that any other loans, grants or advances will be approved. As of April 21, 2020, the Company’s PPP loan has not yet been approved, pending new legislation increasing the pool. The PPP provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. If the Company is successful in obtaining a PPP loan, we intend to use the proceeds for purposes consistent with the PPP and expect to meet the conditions for forgiveness of the loan. Securities Purchase and Exchange Agreement On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “ Securities Purchase and Exchange Agreement 1315 Capital Ampersand Investors Series B Preferred Stock In addition, the Company agreed to exchange $27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the “ Series A Preferred Stock Exchange Shares Exchange The Series B Preferred Stock was offered and sold pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. The shares to be issued upon conversion of the Series B Preferred Stock have not been registered under the Securities Act and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements. In connection with the Company’s application for the PPP loan, both Ampersand and 1315 Capital consented to, and agreed to vote (by proxy or otherwise) their Series B Preferred Stock in favor of any “Fundamental Action” taken by the Company as determined by the Company’s Board of Directors. “Fundamental Actions” include the Company’s ability to a) authorize, create or issue any debt securities for borrowed money or funded debt; b) merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess of $20 million; c) transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Company or any of its direct or indirect subsidiaries, other than those accomplished in the ordinary course of business; d) declare or pay any cash dividend or make any cash distribution on any equity interests of the Company other than the Series B Shares; d) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities; and e) change any accounting methods or practices of the Company, except for those changes required by GAAP or applicable regulatory agencies or authorities. Revolving line of credit Using the proceeds received from the additional financing described above, the Company repaid the $3 million balance on the line of credit in January 2020. As of April 21, 2020, we had $3.4 million outstanding on the Revolving Line. Letter of Credit On March 31, 2020, SVB issued an irrevocable standby letter of credit in the amount of $0.35 million held for security by our Rutherford, NJ landlord pursuant to the July 19, 2019 assignment of the lease. As of March 31, 2020, $0.6 million of our Line of Credit is used to secure the issuances of standby letters of credit by SVB. Nasdaq notification On October 15, 2019, the Company received notice from Nasdaq indicating that the Company had until April 13, 2020 to regain compliance with the minimum bid price requirement of Nasdaq. On January 30, 2020 the Company received notice from Nasdaq stating that the Company was now in compliance with the minimum bid price requirement and that the matter was now closed. However, upon the filing of this Amendment, we will no longer be in compliance with the minimum stockholder equity requirements of Nasdaq.as amended

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts Disclosure	INTERPACE BIOSCIENCES, INC. VALUATION AND QUALIFYING ACCOUNTS YEARS ENDED DECEMBER 31, 2019 AND 2018 ($ in thousands) Additions Balance at (Reductions) (1) Balance at Beginning Charged to Deductions end Description of Period Operations Other of Period 2018 (As Restated) Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance $ 46,308 - 1,587 $ 47,895 2019 (As Restated) Allowance for doubtful accounts $ - - 25 $ 25 Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance $ 47,895 - 5,996 $ 53,891 (1) Includes payments and actual write offs, as well as changes in estimates in the reserves.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Business	Nature of Business Interpace Biosciences, Inc. (the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc. Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has one reporting segment: the Company’s business of developing and selling clinical services and pharma services. The Company’s current reporting segment structure is reflective of the way the Company’s management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.
Accounting Estimates	Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.
Reverse Stock Split	Reverse stock split On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company’s issued and outstanding stock decreased from 39,205,895 to 3,920,589 and 28,694,275 to 2,869,427 at December 31, 2019 and 2018, respectively. All information related to common stock, stock options, restricted stock units, warrants and earnings per share have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.
Accounts Receivable, Net	Accounts Receivable, Net The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s diagnostic services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.
Other Current Assets	Other current assets Other current assets consisted of the following as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Indemnification asset $ - $ 875 Lab supply inventory 1,825 - Prepaid expenses 971 1,230 Funds in escrow 888 - Other 167 65 Total other current assets $ 3,851 $ 2,170
Property and Equipment, Net	Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven to ten years for furniture and fixtures; two to five years for office and computer equipment; three to seven years for lab equipment; and leasehold improvements are amortized over the shorter of the estimated service lives or the terms of the related leases which are currently four to five years. Repairs and maintenance are charged to expense as incurred. Upon disposition, the asset and related accumulated depreciation and amortization are removed from the related accounts and any gains or losses are reflected in operations.
Software Costs	Software Costs Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three to seven years. Software costs that do not meet capitalization criteria are expensed immediately. External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years. Software costs that do not meet capitalization criteria are expensed immediately. See Note 7, Property and Equipment
Long-Lived Assets, Including Finite-lived Intangible Assets	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the Consolidated Statements of Operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
Contingencies	Contingencies In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.
Revenue Recognition	Revenue Recognition Beginning January 1, 2018 under ASC 606, the Company began to recognize revenue for billings less contractual allowances and estimated uncollectable amounts for all payer groups on the accrual basis based upon a thorough analysis of historical receipts (see Note 2, Recent Accounting Standards The Company completed its analysis of the ASC 606 impact and incorporated further analysis of first quarter 2018 collections from its commercial payer base in finalizing its ASC 606 adjustments. The impact of recording the cumulative catch-up adjustment under the modified retrospective method was $2.5 million, recorded as an increase to opening retained earnings on January 1, 2018. Prior periods have not been retrospectively adjusted. The Company also finalized its analysis of modified internal controls over financial reporting and the disclosures required starting with Form 10-Q for the first quarter of 2018. Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known. During 2019, the Company recorded a reduction to revenue of $3.5 million due to a change in estimate of the amounts to be collected from 2018 services. For its pharma services, performance obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Project level fee revenue is recognized ratably over the life of the contract. Some contracts have prepayments prior to services being rendered that are recorded as deferred revenue. These are for study services and setup management. Deferred revenue from pharma services contracts is recorded at fair value and represents payments received in advance of services rendered.
Cost of Revenue	Cost of revenue Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.
Stock-Based Compensation	Stock-Based Compensation The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and stock appreciation rights (“SARs”). The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. See Note 15, Stock-Based Compensation,
Treasury Stock	Treasury Stock Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.
Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 9, Leases
Income Taxes	Income taxes Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense. The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. The Company adjusts accruals for unrecognized tax benefits as facts and circumstances change, such as the progress of a tax audit. However, any adjustments made may be material to the Company’s consolidated results of operations or cash flows for a reporting period. Penalties and interest, if incurred, would be recorded as a component of current income tax expense. Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.
Income (Loss) Per Share	Income (Loss) per Share Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2019 and 2018, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.
Restatement of Previously Issued Consolidated Financial Statements	1B. Restatement of Previously Issued Consolidated Financial Statements We have restated herein our audited consolidated financial statements as of December 31, 2019 and 2018 and for the years ended December 31, 2019 and December 31, 2018. We have also restated impacted amounts within the accompanying footnotes to the consolidated financial statements which have been noted as such. As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assets upon launch of the test. On December 7, 2020, the Company’s management conferred with the Audit Committee of the Company’s Board of Directors and concluded that (1) a non-cash impairment charge for an intangible asset of approximately $12 million should have been recorded during the Company’s 2016 fiscal year; (2) the Company should have initiated amortization of such intangible asset in fiscal 2014 and therefore each of fiscal years 2014, 2015, 2016, 2017, 2018, and 2019 and the first two quarters of fiscal 2020 require adjustment to record amortization expense; (3) the consolidated financial statements contained in the Company’s Annual Reports on Form 10-K for the years ended December 31, 2014, 2015, 2016, 2017, 2018, and 2019, as well as the consolidated financial statements contained in the Quarterly Reports on Form 10-Q for each quarterly period within those fiscal years as well as the quarterly periods ended March 31, 2020 and June 30, 2020, should no longer be relied upon. As a result the Company is restating its consolidated financial statements for the years ended December 31, 2019 and December 31, 2018 in this Form 10-K/A. The following tables present reconciliation from our prior periods as previously reported to the restated values for the consolidated balance sheets and the consolidated statement of operations. A description of misstatements is listed below: a) Amortization expense - We recorded amortization expense starting at the dates of acquisition for our Barrett’s and Thyroid intangible assets. The impact of the additional amortization charge was approximately $700 thousand in Fiscal 2014, $2.3 million in Fiscal 2015, $2.0 million in Fiscal 2016, and $340 thousand for each of Fiscal 2017, 2018 and 2019. b) Asset impairment - We recorded an impairment charge on our Barrett’s intangible asset of approximately $11.6 million in the fourth quarter of 2016. c) Adjustments - Adjustments to correct certain other immaterial errors, including previously unrecorded immaterial adjustments identified in audits of prior years’ financial statements. For the Year Ended December 31, 2014 As Asset Asset Other As Total Assets $ 115,906 $ (695 ) $ - $ - $ 115,211 Stockholders’ Equity 20,122 (695 ) - - 19,427 Net Loss $ (16,073 ) $ (695 ) $ - $ - $ (16,768 ) Earnings Per Share* $ (107.87 ) $ (4.66 ) $ - $ - $ (112.53 ) For the Year Ended December 31, 2015 As Asset Asset Other As Total Assets $ 67,712 $ (2,971 ) $ - $ - $ 64,741 Stockholders’ Equity 13,038 (2,971 ) - - 10,067 Net Loss $ (11,356 ) $ (2,276 ) $ - $ - $ (13,632 ) Earnings Per Share* $ (73.26 ) $ (14.68 ) $ - $ - $ (87.95 ) For the Year Ended December 31, 2016 As Asset Asset Other As Total Assets $ 41,778 $ (5,010 ) $ (11,632 ) $ - $ 25,136 Stockholders’ Equity 6,531 (5,010 ) (11,632 ) - (10,111 ) Net Loss $ (8,332 ) $ (2,039 ) $ (11,632 ) $ - $ (22,003 ) Earnings Per Share* $ (45.78 ) $ (11.20 ) $ (63.91 ) $ - $ (120.90 ) For the Year Ended December 31, 2017 As Asset Asset Other As Total Assets $ 53,598 $ (5,347 ) $ (11,632 ) $ - $ 36,619 Stockholders’ Equity 39,869 (5,347 ) (11,632 ) - 22,890 Net Loss $ (12,216 ) $ (337 ) $ - $ - $ (12,553 ) Earnings Per Share* $ (7.75 ) $ (0.21 ) $ - $ - $ (7.96 ) * Adjusted for reverse stock splits since the filing of the original financial statements. INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 2,321 $ - $ 2,321 Accounts receivable, net 10,197 141 (c) 10,338 Other current assets 3,851 - 3,851 Total current assets 16,369 141 16,510 Property and equipment, net 6,814 - 6,814 Other intangible assets, net 33,501 (17,652 ) (a) (b) 15,849 Goodwill 8,433 - 8,433 Operating lease right of use assets 3,892 - 3,892 Other long-term assets 42 - 42 Total assets $ 69,051 $ (17,511 ) $ 51,540 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 4,812 $ (103 ) (c) $ 4,709 Accrued salary and bonus 2,341 - (c) 2,341 Other accrued expenses 9,379 97 (c) 9,476 Current liabilities from discontinued operations 766 - 766 Total current liabilities 17,298 (6 ) 17,292 Contingent consideration 2,391 - 2,391 Operating lease liabilities, net of current portion 2,591 - 2,591 Line of credit 3,000 - 3,000 Other long-term liabilities 4,573 - 4,573 Total liabilities 29,853 (6 ) 29,847 Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding 26,172 - 26,172 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding; 393 - 393 Additional paid-in capital 182,514 - 182,514 Accumulated deficit (168,160 ) (17,505 ) (a) (b) (c) (185,665 ) Treasury stock, at cost (11,781 shares) (1,721 ) - (1,721 ) Total stockholders’ equity 13,026 (17,505 ) (4,479 ) Total liabilities and stockholders’ equity $ 42,879 $ (17,511 ) $ 25,368 Total liabilities, preferred stock and stockholders’ equity $ 69,051 $ (17,511 ) $ 51,540 INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 6,068 $ - $ 6,068 Accounts receivable, net 9,483 - 9,483 Other current assets 2,170 - 2,170 Total current assets 17,721 - 17,721 Property and equipment, net 837 - 837 Other intangible assets, net 29,853 (17,315 ) (a) (b) 12,538 Other long-term assets 31 - 31 Total assets $ 48,442 $ (17,315 ) $ 31,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,059 $ - $ 1,059 Accrued salary and bonus 1,424 120 (c) 1,544 Other accrued expenses 5,091 57 (c) 5,148 Current liabilities from discontinued operations 918 - 918 Total current liabilities 8,492 177 8,669 Contingent consideration 2,693 - 2,693 Other long-term liabilities 4,319 - 4,319 Total liabilities 15,504 177 15,681 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 2,876,734 shares issued and 2,869,427 shares outstanding; 287 - 287 Additional paid-in capital 175,820 - 175,820 Accumulated deficit (141,489 ) (17,492 ) (a) (b) (c) (158,981 ) Treasury stock, at cost (7,307 shares) (1,680 ) - (1,680 ) Total stockholders’ equity 32,938 (17,492 ) 15,446 Total liabilities and stockholders’ equity $ 48,442 $ (17,315 ) $ 31,127 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 24,079 $ 141 (c) $ 24,220 Cost of revenue 15,888 - 15,888 Gross profit 8,191 141 8,332 Operating expenses: Sales and marketing 11,116 - 11,116 Research and development 2,810 - 2,810 General and administrative 14,546 (183 ) (c) 14,363 Acquisition related expense 2,534 - 2,534 Acquisition related amortization expense 3,652 337 (a) 3,989 Change in fair value of contingent consideration (44 ) - (44 ) Total operating expenses 34,614 154 34,768 Operating loss (26,423 ) (13 ) (26,436 ) Accretion expense (440 ) - (440 ) Other income (expense), net 196 - 196 Loss from continuing operations before tax (26,667 ) (13 ) (26,680 ) (Benefit) provision for income taxes (28 ) - (28 ) Loss from continuing operations (26,639 ) (13 ) (26,652 ) Income from discontinued operations, net of tax (88 ) - (88 ) Net loss $ (26,727 ) $ (13 ) $ (26,740 ) Less dividends on preferred stock $ (429 ) $ - $ (429 ) Net loss attributable to common stockholders $ (27,156 ) $ (13 ) $ (27,169 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (7.23 ) $ (0.00 ) $ (7.23 ) From discontinued operations (0.02 ) - (0.02 ) Net loss per basic and diluted share of common stock $ (7.25 ) $ (0.00 ) $ (7.25 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 21,896 $ - $ 21,896 Cost of revenue 10,197 - 10,197 Gross profit 11,699 - 11,699 Operating expenses: Sales and marketing 8,421 - 8,421 Research and development 2,124 - 2,124 General and administrative 8,499 177 (c) 8,676 Acquisition related amortization expense 3,252 337 (a) 3,589 Change in fair value of contingent consideration 1,522 - 1,522 Total operating expenses 23,818 514 24,332 Operating loss (12,119 ) (514 ) (12,633 ) Accretion expense (331 ) - (331 ) Other income (expense), net 263 - 263 Loss from continuing operations before tax (12,187 ) (514 ) (12,701 ) (Benefit) provision for income taxes 18 - 18 Loss from continuing operations (12,205 ) (514 ) (12,719 ) Income from discontinued operations, net of tax 16 - 16 Net loss $ (12,189 ) $ (514 ) $ (12,703 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (4.33 ) $ (0.19 ) $ (4.52 ) From discontinued operations - - - Net loss per basic and diluted share of common stock $ (4.33 ) $ (0.19 ) $ (4.52 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (in thousands) As Previously Reported As Restated For The Year Ended For The Year Ended December 31, 2019 Restatement Amount Restatement Reference December 31, 2019 Shares Amount Shares Amount Common stock: Balance at January 1 2,877 $ 287 $ - 2,877 $ 287 Common stock issued 9 1 - 9 1 Common stock issued through offerings 933 94 - 933 94 Balance at March 31 3,819 382 - 3,819 382 Common stock issued 10 1 - 10 1 Balance at June 30 3,829 383 - 3,829 383 Common stock issued - - - - - Common stock issued through offerings - - - - - Balance at September 30 3,829 383 - 3,829 383 Common stock issued 5 - - 5 - Common stock issued through market sales 98 10 - 98 10 Balance at December 31 3,932 393 - 3,932 393 Treasury stock: Balance at January 1 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased 3 (32 ) - 3 (32 ) Balance at March 31 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at June 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at September 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased 2 (9 ) - 2 (9 ) Balance at December 31 12 (1,721 ) - 12 (1,721 ) Additional paid-in capital: Balance at January 1 175,820 - 175,820 Common stock issued through offerings, net of expenses 5,868 - 5,868 Stock-based compensation expense 266 - 266 Balance at March 31 181,954 - 181,954 Common stock issued 72 - 72 Stock-based compensation expense 205 - 205 Balance at June 30 182,231 - 182,231 Common stock issued through offerings, net of expenses - - - Dividends accrued (75 ) - (75 ) Stock-based compensation expense 205 - 205 Balance at September 30 182,361 - 182,361 Common stock issued through market sales, net of expenses 218 - 218 Common stock issued - - - Dividends accrued (354 ) - (354 ) Stock-based compensation expense 289 - 289 Balance at December 31 182,514 - 182,514 Accumulated deficit: Balance at January 1 (141,489 ) (17,492 ) (a) (b) (c) (158,981 ) Net loss (3,419 ) 93 (a) (c) (3,326 ) Adoption of ASC 606 - - - Adoption of ASC 842 55 - 55 Balance at March 31 (144,853 ) (17,399 ) (162,252 ) Net loss (5,220 ) (84 ) (a) (5,304 ) Balance at June 30 (150,073 ) (17,483 ) (167,556 ) Net loss (7,362 ) (84 ) (a) (7,446 ) Balance at September 30 (157,435 ) (17,567 ) (175,002 ) Net loss (10,725 ) 62 (a) (c) (10,663 ) Balance at December 31 (168,160 ) (17,505 ) (185,665 ) Total stockholders’ equity $ 13,026 $ (17,505 ) $ (4,479 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (in thousands) As Previously Reported As Restated For The Year Ended For The Year Ended December 31, 2018 Restatement Amount Restatement Reference December 31, 2018 Shares Amount Shares Amount Common stock: Balance at January 1 2,790 $ 278 $ - 2,790 $ 278 Common stock issued 4 1 - 4 1 Common stock issued through offerings - - - - - Balance at March 31 2,794 279 - 2,794 279 Common stock issued 33 3 - 33 3 Balance at June 30 2,827 282 - 2,827 282 Common stock issued 10 1 - 10 1 Common stock issued through offerings - - - - - Balance at September 30 2,837 283 - 2,837 283 Common stock issued 40 4 - 40 4 Common stock issued through market sales - - - - - Balance at December 31 2,877 287 - 2,877 287 Treasury stock: Balance at January 1 6 (1,671 ) - 6 (1,671 ) Treasury stock purchased 1 (9 ) - 1 (9 ) Balance at March 31 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at June 30 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at September 30 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at December 31 7 (1,680 ) - 7 (1,680 ) Additional paid-in capital: Balance at January 1 173,062 - 173,062 Common stock issued through offerings, net of expenses - - - Stock-based compensation expense 597 - 597 Balance at March 31 173,659 - 173,659 Common stock issued 282 - 282 Stock-based compensation expense 419 - 419 Balance at June 30 174,360 - 174,360 Common stock issued 144 - 144 Dividends accrued - - - Stock-based compensation expense 374 - 374 Balance at September 30 174,878 - 174,878 Common stock issued through market sales, net of expenses - - - Common stock issued 598 - 598 Dividends accrued - - - Stock-based compensation expense 344 - 344 Balance at December 31 175,820 - 175,820 Accumulated deficit: Balance at January 1 (131,800 ) (16,978 ) (a) (b) (c) (148,778 ) Net loss (3,193 ) (84 ) (a) (3,277 ) Adoption of ASC 606 2,500 - 2,500 Adoption of ASC 842 - - - Balance at March 31 (132,493 ) (17,062 ) (149,555 ) Net loss (1,917 ) (84 ) (a) (2,001 ) Balance at June 30 (134,410 ) (17,146 ) (151,556 ) Net loss (3,042 ) (84 ) (a) (3,126 ) Balance at September 30 (137,452 ) (17,230 ) (154,682 ) Net loss (4,037 ) (262 ) (a) (c) (4,299 ) Balance at December 31 (141,489 ) (17,492 ) (158,981 ) Total stockholders’ equity $ 32,938 $ (17,492 ) $ 15,446 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF CASH FLOWS (in thousands) For The Year Ended December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated Cash Flows From Operating Activities Net loss $ (26,727 ) $ (13 ) (a) (c) $ (26,740 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 4,187 337 (a) 4,524 Interest accretion 440 - 440 Bad debt expense 499 - 499 Reversal of DOJ accrual - - - Mark to market on warrants (279 ) - (279 ) Stock-based compensation 1,535 - 1,535 Deferred income taxes 18 - 18 Change in estimate on collectability of accounts receivable 3,479 - 3,479 Change in fair value of contingent consideration (44 ) (44 ) Other gains and expenses, net 18 - 18 Other changes in operating assets and liabilities: Increase in accounts receivable (961 ) (141 ) (c) (1,102 ) Decrease (increase) in other current assets 129 - 129 Increase in other long-term assets (11 ) - (11 ) (Decrease) increase in accounts payable (835 ) (103 ) (c) (938 ) Increase in accrued salaries and bonus 482 (120 ) 362 Decrease in accrued liabilities (1,341 ) 40 (c) (1,301 ) Increase (decrease) in long-term liabilities 454 - 454 Net cash used in operating activities (18,957 ) - (18,957 ) Cash Flows From Investing Activity Acquisition of Biopharma, net of cash acquired (13,829 ) - (13,829 ) Purchase of property and equipment (131 ) - (131 ) Sale of property and equipment 13 - 13 Net cash used in investing activity (13,947 ) - (13,947 ) Cash Flows From Financing Activities Issuance of common stock, net of expenses 6,478 - 6,478 Issuance of preferred stock, net of expenses 25,744 - 25,744 Payment of CGIX note and related interest (6,024 ) - (6,024 ) Borrowings on Line of Credit 3,000 - 3,000 Cash paid for repurchase of restricted shares (41 ) - (41 ) Net cash provided by (used in) financing activities 29,157 - 29,157 Net decrease in cash and cash equivalents (3,747 ) - (3,747 ) Cash and cash equivalents – beginning of year 6,068 - 6,068 Cash and cash equivalents – end of year $ 2,321 $ - $ 2,321 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF CASH FLOWS (in thousands) For The Year Ended December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated Cash Flows From Operating Activities Net loss $ (12,189 ) $ (514 ) (a) (c) $ (12,703 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,464 337 (a) 3,801 Interest accretion 331 - 331 Reversal of DOJ accrual (350 ) - (350 ) Mark to market on warrants 112 - 112 Stock-based compensation 2,270 - 2,270 Change in fair value of contingent consideration 1,522 1,522 Other changes in operating assets and liabilities: Increase in accounts receivable (3,546 ) - (3,546 ) Increase in other current assets (501 ) - (501 ) Increase in accounts payable 668 - 668 Increase in accrued salaries and bonus 30 120 (c) 150 Decrease in accrued liabilities (402 ) 57 (c) (345 ) Increase (decrease) in long-term liabilities (82 ) - (82 ) Net cash used in operating activities (8,673 ) - (8,673 ) Cash Flows From Investing Activity Purchase of property and equipment (449 ) - (449 ) Net cash used in investing activity (449 ) - (449 ) Cash Flows From Financing Activities Cash paid for repurchase of restricted shares (9 ) - (9 ) Net cash provided by (used in) financing activities (9 ) - (9 ) Net decrease in cash and cash equivalents (9,131 ) - (9,131 ) Cash and cash equivalents – beginning of year 15,199 - 15,199 Cash and cash equivalents – end of year $ 6,068 $ - $ 6,068 The following tables represent the first, second, and third quarters for 2014-2017 that were materially impacted by the restatement as shown below. September 30, 2014 As Reported Asset Asset Other As Restated Total Assets $ 62,227 $ (118 ) $ - $ - $ 62,109 Stockholders’ Equity 25,424 (118 ) - - 25,306 Three Months Ended September 30, 2014 Net Loss $ (4,336 ) $ (118 ) $ - $ - $ (4,454 ) Earnings Per Share* $ (29.10 ) $ (0.79 ) $ - $ - $ (29.89 ) March 31, 2015 As Reported Asset Asset Other As Restated Total Assets $ 112,612 $ (1,441 ) $ - $ - $ 111,171 Stockholders’ Equity 16,624 (1,441 ) - - 15,183 Three Months Ended March 31, 2015 Net Loss $ (3,868 ) $ (746 ) $ - $ - $ (4,614 ) Earnings Per Share* $ (25.79 ) $ (4.97 ) $ - $ - $ (30.76 ) June 30, 2015 As Reported Asset Asset Other As Restated Total Assets $ 107,573 $ (1,951 ) $ - $ - $ 105,622 Stockholders’ Equity 10,298 (1,951 ) - - 8,347 Three Months Ended June 30, 2015 Net Loss $ (6,978 ) $ (510 ) $ - $ - $ (7,488 ) Earnings Per Share* $ (45.91 ) $ (3.36 ) $ - $ - $ (49.26 ) September 30, 2015 As Reported Asset Asset Other As Restated Total Assets $ 99,287 $ (2,461 ) $ - $ - $ 96,826 Stockholders’ Equity 5,861 (2,461 ) - - 3,400 Three Months Ended September 30, 2015 Net Loss $ (4,895 ) $ (510 ) $ - $ - $ (5,405 ) Earnings Per Share* $ (31.18 ) $ (3.25 ) $ - $ - $ (34.43 ) March 31, 2016 As Reported Asset Asset Other As Restated Total Assets $ 56,775 $ (3,480 ) $ - $ - $ 53,295 Stockholders’ Equity 8,306 (3,480 ) - - 4,826 Three Months Ended March 31, 2016 Net Loss $ (4,786 ) $ (510 ) $ - $ - $ (5,296 ) Earnings Per Share* $ (26.89 ) $ (2.87 ) $ - $ - $ (29.75 ) June 30, 2016 As Reported Asset Asset Other As Restated Total Assets $ 53,510 $ (3,990 ) $ - $ - $ 49,520 Stockholders’ Equity 5,993 (3,990 ) - - 2,003 Three Months Ended June 30, 2016 Net Loss $ (2,334 ) $ (510 ) $ - $ - $ (2,844 ) Earnings Per Share* $ (12.82 ) $ (2.80 ) $ - $ - $ (15.63 ) September 30, 2016 As Reported Asset Asset Other As Restated Total Assets $ 45,964 $ (4,500 ) $ - $ - $ 41,464 Stockholders’ Equity (1,479 ) (4,500 ) - - (5,979 ) Three Months Ended September 30, 2016 Net Loss $ (7,493 ) $ (510 ) $ - $ - $ (8,003 ) Earnings Per Share* $ (41.17 ) $ (2.80 ) $ - $ - $ (43.97 ) March 31, 2017 As Reported Asset Asset Other As Restated Total Assets $ 46,975 $ (5,094 ) $ (11,632 ) $ - $ 30,249 Stockholders’ Equity 24,569 (5,094 ) (11,632 ) - 7,843 Three Months Ended March 31, 2017 Net Income (Loss) $ 2,414 $ (84 ) $ - $ - $ 2,330 Earnings Per Share* $ 5.51 $ (0.19 ) $ - $ - $ 5.32 June 30, 2017 As Reported Asset Asset Other As Restated Total Assets $ 53,744 $ (5,178 ) $ (11,632 ) $ - $ 36,934 Stockholders’ Equity 36,342 (5,178 ) (11,632 ) - 19,532 Three Months Ended June 30, 2017 Net Loss $ (6,306 ) $ (84 ) $ - $ - $ (6,390 ) Earnings Per Share* $ (6.53 ) $ (0.09 ) $ - $ - $ (6.61 ) September 30, 2017 As Reported Asset Asset Other As Restated Total Assets $ 50,391 $ (5,262 ) $ (11,632 ) $ - $ 33,497 Stockholders’ Equity 36,378 (5,262 ) (11,632 ) - 19,484 Three Months Ended September 30, 2017 Net Loss $ (3,316 ) $ (84 ) $ - $ - $ (3,400 ) Earnings Per Share* $ (1.51 ) $ (0.04 ) $ - $ - $ (1.54 ) *

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Indemnification asset $ - $ 875 Lab supply inventory 1,825 - Prepaid expenses 971 1,230 Funds in escrow 888 - Other 167 65 Total other current assets $ 3,851 $ 2,170
Schedule of Misstatements of Assets	For the Year Ended December 31, 2014 As Asset Asset Other As Total Assets $ 115,906 $ (695 ) $ - $ - $ 115,211 Stockholders’ Equity 20,122 (695 ) - - 19,427 Net Loss $ (16,073 ) $ (695 ) $ - $ - $ (16,768 ) Earnings Per Share* $ (107.87 ) $ (4.66 ) $ - $ - $ (112.53 ) For the Year Ended December 31, 2015 As Asset Asset Other As Total Assets $ 67,712 $ (2,971 ) $ - $ - $ 64,741 Stockholders’ Equity 13,038 (2,971 ) - - 10,067 Net Loss $ (11,356 ) $ (2,276 ) $ - $ - $ (13,632 ) Earnings Per Share* $ (73.26 ) $ (14.68 ) $ - $ - $ (87.95 ) For the Year Ended December 31, 2016 As Asset Asset Other As Total Assets $ 41,778 $ (5,010 ) $ (11,632 ) $ - $ 25,136 Stockholders’ Equity 6,531 (5,010 ) (11,632 ) - (10,111 ) Net Loss $ (8,332 ) $ (2,039 ) $ (11,632 ) $ - $ (22,003 ) Earnings Per Share* $ (45.78 ) $ (11.20 ) $ (63.91 ) $ - $ (120.90 ) For the Year Ended December 31, 2017 As Asset Asset Other As Total Assets $ 53,598 $ (5,347 ) $ (11,632 ) $ - $ 36,619 Stockholders’ Equity 39,869 (5,347 ) (11,632 ) - 22,890 Net Loss $ (12,216 ) $ (337 ) $ - $ - $ (12,553 ) Earnings Per Share* $ (7.75 ) $ (0.21 ) $ - $ - $ (7.96 ) * Adjusted for reverse stock splits since the filing of the original financial statements.
Schedule of Restatement of Previously Issued Consolidated Financial Statements	INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 2,321 $ - $ 2,321 Accounts receivable, net 10,197 141 (c) 10,338 Other current assets 3,851 - 3,851 Total current assets 16,369 141 16,510 Property and equipment, net 6,814 - 6,814 Other intangible assets, net 33,501 (17,652 ) (a) (b) 15,849 Goodwill 8,433 - 8,433 Operating lease right of use assets 3,892 - 3,892 Other long-term assets 42 - 42 Total assets $ 69,051 $ (17,511 ) $ 51,540 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 4,812 $ (103 ) (c) $ 4,709 Accrued salary and bonus 2,341 - (c) 2,341 Other accrued expenses 9,379 97 (c) 9,476 Current liabilities from discontinued operations 766 - 766 Total current liabilities 17,298 (6 ) 17,292 Contingent consideration 2,391 - 2,391 Operating lease liabilities, net of current portion 2,591 - 2,591 Line of credit 3,000 - 3,000 Other long-term liabilities 4,573 - 4,573 Total liabilities 29,853 (6 ) 29,847 Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding 26,172 - 26,172 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding; 393 - 393 Additional paid-in capital 182,514 - 182,514 Accumulated deficit (168,160 ) (17,505 ) (a) (b) (c) (185,665 ) Treasury stock, at cost (11,781 shares) (1,721 ) - (1,721 ) Total stockholders’ equity 13,026 (17,505 ) (4,479 ) Total liabilities and stockholders’ equity $ 42,879 $ (17,511 ) $ 25,368 Total liabilities, preferred stock and stockholders’ equity $ 69,051 $ (17,511 ) $ 51,540 INTERPACE BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEET (in thousands, except share and per share data) December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated ASSETS Current assets: Cash and cash equivalents $ 6,068 $ - $ 6,068 Accounts receivable, net 9,483 - 9,483 Other current assets 2,170 - 2,170 Total current assets 17,721 - 17,721 Property and equipment, net 837 - 837 Other intangible assets, net 29,853 (17,315 ) (a) (b) 12,538 Other long-term assets 31 - 31 Total assets $ 48,442 $ (17,315 ) $ 31,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,059 $ - $ 1,059 Accrued salary and bonus 1,424 120 (c) 1,544 Other accrued expenses 5,091 57 (c) 5,148 Current liabilities from discontinued operations 918 - 918 Total current liabilities 8,492 177 8,669 Contingent consideration 2,693 - 2,693 Other long-term liabilities 4,319 - 4,319 Total liabilities 15,504 177 15,681 Stockholders’ equity: Common stock, $.01 par value; 100,000,000 shares authorized; 2,876,734 shares issued and 2,869,427 shares outstanding; 287 - 287 Additional paid-in capital 175,820 - 175,820 Accumulated deficit (141,489 ) (17,492 ) (a) (b) (c) (158,981 ) Treasury stock, at cost (7,307 shares) (1,680 ) - (1,680 ) Total stockholders’ equity 32,938 (17,492 ) 15,446 Total liabilities and stockholders’ equity $ 48,442 $ (17,315 ) $ 31,127 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 24,079 $ 141 (c) $ 24,220 Cost of revenue 15,888 - 15,888 Gross profit 8,191 141 8,332 Operating expenses: Sales and marketing 11,116 - 11,116 Research and development 2,810 - 2,810 General and administrative 14,546 (183 ) (c) 14,363 Acquisition related expense 2,534 - 2,534 Acquisition related amortization expense 3,652 337 (a) 3,989 Change in fair value of contingent consideration (44 ) - (44 ) Total operating expenses 34,614 154 34,768 Operating loss (26,423 ) (13 ) (26,436 ) Accretion expense (440 ) - (440 ) Other income (expense), net 196 - 196 Loss from continuing operations before tax (26,667 ) (13 ) (26,680 ) (Benefit) provision for income taxes (28 ) - (28 ) Loss from continuing operations (26,639 ) (13 ) (26,652 ) Income from discontinued operations, net of tax (88 ) - (88 ) Net loss $ (26,727 ) $ (13 ) $ (26,740 ) Less dividends on preferred stock $ (429 ) $ - $ (429 ) Net loss attributable to common stockholders $ (27,156 ) $ (13 ) $ (27,169 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (7.23 ) $ (0.00 ) $ (7.23 ) From discontinued operations (0.02 ) - (0.02 ) Net loss per basic and diluted share of common stock $ (7.25 ) $ (0.00 ) $ (7.25 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except for per share data) For The Year Ended December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated Revenue, net $ 21,896 $ - $ 21,896 Cost of revenue 10,197 - 10,197 Gross profit 11,699 - 11,699 Operating expenses: Sales and marketing 8,421 - 8,421 Research and development 2,124 - 2,124 General and administrative 8,499 177 (c) 8,676 Acquisition related amortization expense 3,252 337 (a) 3,589 Change in fair value of contingent consideration 1,522 - 1,522 Total operating expenses 23,818 514 24,332 Operating loss (12,119 ) (514 ) (12,633 ) Accretion expense (331 ) - (331 ) Other income (expense), net 263 - 263 Loss from continuing operations before tax (12,187 ) (514 ) (12,701 ) (Benefit) provision for income taxes 18 - 18 Loss from continuing operations (12,205 ) (514 ) (12,719 ) Income from discontinued operations, net of tax 16 - 16 Net loss $ (12,189 ) $ (514 ) $ (12,703 ) Basic and diluted (loss) income per share of common stock: From continuing operations $ (4.33 ) $ (0.19 ) $ (4.52 ) From discontinued operations - - - Net loss per basic and diluted share of common stock $ (4.33 ) $ (0.19 ) $ (4.52 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (in thousands) As Previously Reported As Restated For The Year Ended For The Year Ended December 31, 2019 Restatement Amount Restatement Reference December 31, 2019 Shares Amount Shares Amount Common stock: Balance at January 1 2,877 $ 287 $ - 2,877 $ 287 Common stock issued 9 1 - 9 1 Common stock issued through offerings 933 94 - 933 94 Balance at March 31 3,819 382 - 3,819 382 Common stock issued 10 1 - 10 1 Balance at June 30 3,829 383 - 3,829 383 Common stock issued - - - - - Common stock issued through offerings - - - - - Balance at September 30 3,829 383 - 3,829 383 Common stock issued 5 - - 5 - Common stock issued through market sales 98 10 - 98 10 Balance at December 31 3,932 393 - 3,932 393 Treasury stock: Balance at January 1 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased 3 (32 ) - 3 (32 ) Balance at March 31 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at June 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased - - - - - Balance at September 30 10 (1,712 ) - 10 (1,712 ) Treasury stock purchased 2 (9 ) - 2 (9 ) Balance at December 31 12 (1,721 ) - 12 (1,721 ) Additional paid-in capital: Balance at January 1 175,820 - 175,820 Common stock issued through offerings, net of expenses 5,868 - 5,868 Stock-based compensation expense 266 - 266 Balance at March 31 181,954 - 181,954 Common stock issued 72 - 72 Stock-based compensation expense 205 - 205 Balance at June 30 182,231 - 182,231 Common stock issued through offerings, net of expenses - - - Dividends accrued (75 ) - (75 ) Stock-based compensation expense 205 - 205 Balance at September 30 182,361 - 182,361 Common stock issued through market sales, net of expenses 218 - 218 Common stock issued - - - Dividends accrued (354 ) - (354 ) Stock-based compensation expense 289 - 289 Balance at December 31 182,514 - 182,514 Accumulated deficit: Balance at January 1 (141,489 ) (17,492 ) (a) (b) (c) (158,981 ) Net loss (3,419 ) 93 (a) (c) (3,326 ) Adoption of ASC 606 - - - Adoption of ASC 842 55 - 55 Balance at March 31 (144,853 ) (17,399 ) (162,252 ) Net loss (5,220 ) (84 ) (a) (5,304 ) Balance at June 30 (150,073 ) (17,483 ) (167,556 ) Net loss (7,362 ) (84 ) (a) (7,446 ) Balance at September 30 (157,435 ) (17,567 ) (175,002 ) Net loss (10,725 ) 62 (a) (c) (10,663 ) Balance at December 31 (168,160 ) (17,505 ) (185,665 ) Total stockholders’ equity $ 13,026 $ (17,505 ) $ (4,479 ) INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (in thousands) As Previously Reported As Restated For The Year Ended For The Year Ended December 31, 2018 Restatement Amount Restatement Reference December 31, 2018 Shares Amount Shares Amount Common stock: Balance at January 1 2,790 $ 278 $ - 2,790 $ 278 Common stock issued 4 1 - 4 1 Common stock issued through offerings - - - - - Balance at March 31 2,794 279 - 2,794 279 Common stock issued 33 3 - 33 3 Balance at June 30 2,827 282 - 2,827 282 Common stock issued 10 1 - 10 1 Common stock issued through offerings - - - - - Balance at September 30 2,837 283 - 2,837 283 Common stock issued 40 4 - 40 4 Common stock issued through market sales - - - - - Balance at December 31 2,877 287 - 2,877 287 Treasury stock: Balance at January 1 6 (1,671 ) - 6 (1,671 ) Treasury stock purchased 1 (9 ) - 1 (9 ) Balance at March 31 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at June 30 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at September 30 7 (1,680 ) - 7 (1,680 ) Treasury stock purchased - - - - - Balance at December 31 7 (1,680 ) - 7 (1,680 ) Additional paid-in capital: Balance at January 1 173,062 - 173,062 Common stock issued through offerings, net of expenses - - - Stock-based compensation expense 597 - 597 Balance at March 31 173,659 - 173,659 Common stock issued 282 - 282 Stock-based compensation expense 419 - 419 Balance at June 30 174,360 - 174,360 Common stock issued 144 - 144 Dividends accrued - - - Stock-based compensation expense 374 - 374 Balance at September 30 174,878 - 174,878 Common stock issued through market sales, net of expenses - - - Common stock issued 598 - 598 Dividends accrued - - - Stock-based compensation expense 344 - 344 Balance at December 31 175,820 - 175,820 Accumulated deficit: Balance at January 1 (131,800 ) (16,978 ) (a) (b) (c) (148,778 ) Net loss (3,193 ) (84 ) (a) (3,277 ) Adoption of ASC 606 2,500 - 2,500 Adoption of ASC 842 - - - Balance at March 31 (132,493 ) (17,062 ) (149,555 ) Net loss (1,917 ) (84 ) (a) (2,001 ) Balance at June 30 (134,410 ) (17,146 ) (151,556 ) Net loss (3,042 ) (84 ) (a) (3,126 ) Balance at September 30 (137,452 ) (17,230 ) (154,682 ) Net loss (4,037 ) (262 ) (a) (c) (4,299 ) Balance at December 31 (141,489 ) (17,492 ) (158,981 ) Total stockholders’ equity $ 32,938 $ (17,492 ) $ 15,446 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF CASH FLOWS (in thousands) For The Year Ended December 31, 2019 As Previously Reported Restatement Amount Restatement Reference As Restated Cash Flows From Operating Activities Net loss $ (26,727 ) $ (13 ) (a) (c) $ (26,740 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 4,187 337 (a) 4,524 Interest accretion 440 - 440 Bad debt expense 499 - 499 Reversal of DOJ accrual - - - Mark to market on warrants (279 ) - (279 ) Stock-based compensation 1,535 - 1,535 Deferred income taxes 18 - 18 Change in estimate on collectability of accounts receivable 3,479 - 3,479 Change in fair value of contingent consideration (44 ) (44 ) Other gains and expenses, net 18 - 18 Other changes in operating assets and liabilities: Increase in accounts receivable (961 ) (141 ) (c) (1,102 ) Decrease (increase) in other current assets 129 - 129 Increase in other long-term assets (11 ) - (11 ) (Decrease) increase in accounts payable (835 ) (103 ) (c) (938 ) Increase in accrued salaries and bonus 482 (120 ) 362 Decrease in accrued liabilities (1,341 ) 40 (c) (1,301 ) Increase (decrease) in long-term liabilities 454 - 454 Net cash used in operating activities (18,957 ) - (18,957 ) Cash Flows From Investing Activity Acquisition of Biopharma, net of cash acquired (13,829 ) - (13,829 ) Purchase of property and equipment (131 ) - (131 ) Sale of property and equipment 13 - 13 Net cash used in investing activity (13,947 ) - (13,947 ) Cash Flows From Financing Activities Issuance of common stock, net of expenses 6,478 - 6,478 Issuance of preferred stock, net of expenses 25,744 - 25,744 Payment of CGIX note and related interest (6,024 ) - (6,024 ) Borrowings on Line of Credit 3,000 - 3,000 Cash paid for repurchase of restricted shares (41 ) - (41 ) Net cash provided by (used in) financing activities 29,157 - 29,157 Net decrease in cash and cash equivalents (3,747 ) - (3,747 ) Cash and cash equivalents – beginning of year 6,068 - 6,068 Cash and cash equivalents – end of year $ 2,321 $ - $ 2,321 INTERPACE BIOSCIENCES, INC. CONSOLIDATED STATEMENT OF CASH FLOWS (in thousands) For The Year Ended December 31, 2018 As Previously Reported Restatement Amount Restatement Reference As Restated Cash Flows From Operating Activities Net loss $ (12,189 ) $ (514 ) (a) (c) $ (12,703 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,464 337 (a) 3,801 Interest accretion 331 - 331 Reversal of DOJ accrual (350 ) - (350 ) Mark to market on warrants 112 - 112 Stock-based compensation 2,270 - 2,270 Change in fair value of contingent consideration 1,522 1,522 Other changes in operating assets and liabilities: Increase in accounts receivable (3,546 ) - (3,546 ) Increase in other current assets (501 ) - (501 ) Increase in accounts payable 668 - 668 Increase in accrued salaries and bonus 30 120 (c) 150 Decrease in accrued liabilities (402 ) 57 (c) (345 ) Increase (decrease) in long-term liabilities (82 ) - (82 ) Net cash used in operating activities (8,673 ) - (8,673 ) Cash Flows From Investing Activity Purchase of property and equipment (449 ) - (449 ) Net cash used in investing activity (449 ) - (449 ) Cash Flows From Financing Activities Cash paid for repurchase of restricted shares (9 ) - (9 ) Net cash provided by (used in) financing activities (9 ) - (9 ) Net decrease in cash and cash equivalents (9,131 ) - (9,131 ) Cash and cash equivalents – beginning of year 15,199 - 15,199 Cash and cash equivalents – end of year $ 6,068 $ - $ 6,068
Schedule of Materially Impacted by the Restatement	The following tables represent the first, second, and third quarters for 2014-2017 that were materially impacted by the restatement as shown below. September 30, 2014 As Reported Asset Asset Other As Restated Total Assets $ 62,227 $ (118 ) $ - $ - $ 62,109 Stockholders’ Equity 25,424 (118 ) - - 25,306 Three Months Ended September 30, 2014 Net Loss $ (4,336 ) $ (118 ) $ - $ - $ (4,454 ) Earnings Per Share* $ (29.10 ) $ (0.79 ) $ - $ - $ (29.89 ) March 31, 2015 As Reported Asset Asset Other As Restated Total Assets $ 112,612 $ (1,441 ) $ - $ - $ 111,171 Stockholders’ Equity 16,624 (1,441 ) - - 15,183 Three Months Ended March 31, 2015 Net Loss $ (3,868 ) $ (746 ) $ - $ - $ (4,614 ) Earnings Per Share* $ (25.79 ) $ (4.97 ) $ - $ - $ (30.76 ) June 30, 2015 As Reported Asset Asset Other As Restated Total Assets $ 107,573 $ (1,951 ) $ - $ - $ 105,622 Stockholders’ Equity 10,298 (1,951 ) - - 8,347 Three Months Ended June 30, 2015 Net Loss $ (6,978 ) $ (510 ) $ - $ - $ (7,488 ) Earnings Per Share* $ (45.91 ) $ (3.36 ) $ - $ - $ (49.26 ) September 30, 2015 As Reported Asset Asset Other As Restated Total Assets $ 99,287 $ (2,461 ) $ - $ - $ 96,826 Stockholders’ Equity 5,861 (2,461 ) - - 3,400 Three Months Ended September 30, 2015 Net Loss $ (4,895 ) $ (510 ) $ - $ - $ (5,405 ) Earnings Per Share* $ (31.18 ) $ (3.25 ) $ - $ - $ (34.43 ) March 31, 2016 As Reported Asset Asset Other As Restated Total Assets $ 56,775 $ (3,480 ) $ - $ - $ 53,295 Stockholders’ Equity 8,306 (3,480 ) - - 4,826 Three Months Ended March 31, 2016 Net Loss $ (4,786 ) $ (510 ) $ - $ - $ (5,296 ) Earnings Per Share* $ (26.89 ) $ (2.87 ) $ - $ - $ (29.75 ) June 30, 2016 As Reported Asset Asset Other As Restated Total Assets $ 53,510 $ (3,990 ) $ - $ - $ 49,520 Stockholders’ Equity 5,993 (3,990 ) - - 2,003 Three Months Ended June 30, 2016 Net Loss $ (2,334 ) $ (510 ) $ - $ - $ (2,844 ) Earnings Per Share* $ (12.82 ) $ (2.80 ) $ - $ - $ (15.63 ) September 30, 2016 As Reported Asset Asset Other As Restated Total Assets $ 45,964 $ (4,500 ) $ - $ - $ 41,464 Stockholders’ Equity (1,479 ) (4,500 ) - - (5,979 ) Three Months Ended September 30, 2016 Net Loss $ (7,493 ) $ (510 ) $ - $ - $ (8,003 ) Earnings Per Share* $ (41.17 ) $ (2.80 ) $ - $ - $ (43.97 ) March 31, 2017 As Reported Asset Asset Other As Restated Total Assets $ 46,975 $ (5,094 ) $ (11,632 ) $ - $ 30,249 Stockholders’ Equity 24,569 (5,094 ) (11,632 ) - 7,843 Three Months Ended March 31, 2017 Net Income (Loss) $ 2,414 $ (84 ) $ - $ - $ 2,330 Earnings Per Share* $ 5.51 $ (0.19 ) $ - $ - $ 5.32 June 30, 2017 As Reported Asset Asset Other As Restated Total Assets $ 53,744 $ (5,178 ) $ (11,632 ) $ - $ 36,934 Stockholders’ Equity 36,342 (5,178 ) (11,632 ) - 19,532 Three Months Ended June 30, 2017 Net Loss $ (6,306 ) $ (84 ) $ - $ - $ (6,390 ) Earnings Per Share* $ (6.53 ) $ (0.09 ) $ - $ - $ (6.61 ) September 30, 2017 As Reported Asset Asset Other As Restated Total Assets $ 50,391 $ (5,262 ) $ (11,632 ) $ - $ 33,497 Stockholders’ Equity 36,378 (5,262 ) (11,632 ) - 19,484 Three Months Ended September 30, 2017 Net Loss $ (3,316 ) $ (84 ) $ - $ - $ (3,400 ) Earnings Per Share* $ (1.51 ) $ (0.04 ) $ - $ - $ (1.54 ) *

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	The reconciliation of consideration given for BioPharma to the preliminary allocation of the purchase price of assets and liabilities acquired based on their relative fair values is as follows: Cash $ 13,829 Subordinated note payable 6,822 Total consideration $ 20,651 Assets acquired Accounts receivable $ 3,731 Accrued revenue 289 Lab supplies 877 Prepaid expenses 266 Property and equipment 6,412 Operating lease assets 2,187 Acquired identifiable intangible assets: Trademarks and trade name 1,600 Customer relationships 5,700 Total acquired identifiable intangible assets 7,300 Goodwill 8,273 Total assets acquired 29,335 Liabilities assumed Accounts payable (4,535 ) Accrued liabilities (435 ) Deferred revenue (1,076 ) Operating lease liabilities (2,187 ) Finance lease liabilities (451 ) Total liabilities assumed (8,684 ) Net assets acquired $ 20,651
Schedule of ProForma Information	Years Ended December 31, December 31, 2019 2018 Revenue $ 31,722 $ 37,218

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations Amount Recognized in Balance Sheet	The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2019 and December 31, 2018: December 31, 2019 December 31, 2018 Accounts payable $ - $ 192 Accrued liabilities 766 726 Current liabilities from discontinued operations 766 918 Total liabilities $ 766 $ 918

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Financial Instrument Measured on Recurring Basis	The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below. As of December 31, 2019 Fair Value Measurements Carrying Fair As of December 31, 2019 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,893 $ 2,893 $ - $ - $ 2,893 Other long-term liabilities: Warrant liability (2) 82 82 - - 82 $ 2,975 $ 2,975 $ - $ - $ 2,975 As of December 31, 2018 Fair Value Measurements Carrying Fair As of December 31, 2018 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen $ 3,127 $ 3,127 $ - $ - $ 3,127 Other long-term liabilities: Warrant liability 361 361 - - 361 $ 3,488 $ 3,488 $ - $ - $ 3,488
Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. Cancellation Adjustment of Obligation/ to Fair Value/ December 31, 2018 Payments Accretion Conversions Exercises Mark to Market December 31, 2019 Asuragen $ 3,127 $ (630 ) $ 440 $ - $ (44 ) $ 2,893 Underwriters Warrants 361 - - - (279 ) 82 $ 3,488 $ (630 ) $ 440 $ - $ (323 ) $ 2,975

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following as of December 31, 2019 and 2018: December 31, 2019 2018 Furniture and fixtures $ 242 $ 62 Lab and office equipment 6,353 1,686 Computer equipment 339 172 Internal-use software 1,276 113 Leasehold improvements 506 175 Property and equipment 8,716 2,208 Less accumulated depreciation and amortization (1,902 ) (1,371 ) Net property and equipment $ 6,814 $ 837

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets Carrying Value	The net carrying value of the identifiable intangible assets as of December 31, 2019 and December 31, 2018 is as follows: As Restated As Restated As of December 31, 2019 As of December 31, 2018 Life Carrying Carrying (Years) Amount Amount Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,719 6,719 BioPharma acquisition: Trademarks 10 1,600 - Customer relationships 8 5,700 - CLIA Lab 2.3 $ 609 $ 609 Total $ 39,288 $ 31,988 Accumulated Amortization $ (23,439 ) $ (19,450 ) Net Carrying Value $ 15,849 $ 12,538
Schedule of Goodwill Carrying Value	The following table displays a roll forward of the carrying amount of goodwill from January 1, 2018 to December 31, 2019: Carrying Amount Balance as of January 1, 2018 $ - Balance as of December 31, 2018 - Goodwill acquired 8,273 Adjustments 160 Balance as of December 31, 2019 $ 8,433
Schedule of Future Estimated Amortization Expense	Amortization expense was approximately $4.0 million and $3.6 million for the years ended December 31, 2019 and 2018, respectively. Estimated amortization expense for the next five years is as follows: As Restated 2020 2021 2022 2023 2024 $ 4,871 $ 4,078 $ 2,156 $ 1,745 $ 873

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Financing and Operating Leases	The table below presents the lease-related assets and liabilities recorded in the Consolidated Balance Sheet: Classification on the Balance Sheet December 31, 2019 Assets Financing lease assets Property and equipment, net $ 998 Operating lease assets Operating lease right of use assets 3,892 Total lease assets $ 4,890 Liabilities Current Financing lease liabilities Other accrued expenses $ 184 Operating lease liabilities Other accrued expenses 1,321 Total current lease liabilities $ 1,505 Noncurrent Financing lease liabilities Other long-term liabilities 123 Operating lease liabilities Operating lease liabilities, net of current portion 2,591 Total long-term lease liabilities 2,714 Total lease liabilities $ 4,219
Schedule of Maturities of Operating and Financing Lease Liabilties	The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2019: Operating Leases Financing Leases 2020 1,472 226 2021 1,295 120 2022 1,223 13 2023 344 - Total minimum lease payments 4,334 359 Less: amount of lease payments representing effects of discounting 418 52 Present value of future minimum lease payments 3,916 307 Less: current obligations under leases 1,321 184 Long-term lease obligations $ 2,595 $ 123

Accrued Expenses and Other Lo_2

Accrued Expenses and Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	Other accrued expenses consisted of the following as of December 31, 2019 and 2018: As Restated As Restated December 31, 2019 December 31, 2018 Accrued royalties $ 1,934 $ 1,399 Indemnification liability - 875 Contingent consideration 502 434 Operating lease liability 1,321 - Financing lease liability 184 - Deferred revenue 457 - Payable to CGI 888 - Accrued sales and marketing - diagnostics 197 - Accrued lab costs - diagnostics 163 150 Accrued professional fees 1,399 758 Taxes payable 403 285 Unclaimed property 565 565 All others 1,463 682 Total other accrued expenses $ 9,476 $ 5,148
Schedule of Other Long Term Liabilities	Other long-term liabilities consisted of the following as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Warrant liability $ 82 $ 361 Uncertain tax positions 4,081 3,838 Deferred revenue 269 - Other 141 120 Total other long-term liabilities $ 4,573 $ 4,319

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Obligation, Fiscal Year Maturity	As of December 31, 2019, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year are as follows: Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 4,334 $ 1,472 $ 2,518 $ 344 $ - Total $ 4,334 $ 1,472 $ 2,518 $ 344 $ -

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants
Schedule of Warrants Outstanding and Warrants Activity	Warrants outstanding and warrant activity for the year ended December 31, 2019 are as follows: Description Classification Exercise Price Expiration Date Warrants Issued Warrants Exercised Warrants Cancelled/ Expired Balance Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 - - 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 - - 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 - (4,000 ) 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 (567,286 ) - 870,214 870,214 Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 - - 15,000 15,000 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 - - 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 - - - 65,434 1,990,934 (567,286 ) (4,000 ) 1,354,214 1,419,648

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2019 and December 31, 2018. December 31, 2019 December 31, 2018 Risk-free interest rate 2.34 % 2.71 % Expected life 5.9 years 6.0 years Expected volatility 128.58 % 127.18 % Dividend yield - -
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award	The impact of RSUs and stock options on net loss for the years ended December 31, 2019 and 2018 is as follows: 2019 2018 RSUs $ 243 $ 301 Options 722 1,433 Total stock-based compensation expense $ 965 $ 1,734
Schedule of Stock Option Activity	A summary of stock option and SARs activity for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Price Weighted-Average Remaining Contractual Period (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 288,950 $ 21.40 8.83 $ - Granted 132,545 9.50 9.30 - Exercised - Forfeited or expired (5,817 ) 387.10 - Outstanding at December 31, 2019 415,678 12.50 8.45 - Exercisable at December 31, 2019 202,206 15.20 7.91 - Vested and expected to vest 402,921 12.60 8.43 -
Schedule of Non Vested Option Activity	A summary of the status of the Company’s non-vested options for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Date Fair Value Non-vested at January 1, 2019 134,089 $ 9.30 Granted 132,545 8.50 Vested (53,150 ) 9.00 Forfeited - - Non-vested at December 31, 2019 213,484 $ 8.80
Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the Company’s non-vested shares of restricted stock units for the year ended December 31, 2019, and changes during such year, is presented below: Shares Weighted- Average Grant Date Fair Value Average Remaining Vesting Period (in years) Aggregate Intrinsic Value Non-vested at January 1, 2019 36,224 $ 11.70 1.37 $ 289,758 Granted 27,637 9.80 - - Vested (14,486 ) 13.70 - - Forfeited - - - - Non-vested at December 31, 2019 49,375 $ 10.00 1.11 $ 246,875

Revenue Sources (Tables)

Revenue Sources (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of Revenue by Major Customers	Years Ended December 31, Customer 2019 2018 Medicare $ 10,605 $ 9,114 Commercial Payors $ 7,589 $ 4,079 Client Billings $ 3,521 $ 3,621 Medicare Advantage $ 1,912 $ 3,011

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The benefit from income taxes on continuing operations for the years ended December 31, 2019 and 2018 is comprised of the following: 2019 2018 Current: Federal $ (46 ) $ (2 ) State - 20 Total current (46 ) 18 Deferred: Federal 11 - State 7 - Total deferred 18 - Benefit from income taxes $ (28 ) $ 18
Schedule of Deferred Tax Assets and Liabilities	The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2019 and 2018 are as follows: As Restated As Restated 2019 2018 Deferred tax assets: Federal net operating loss carryforwards $ 44,152 $ 40,158 State net operating loss carryforwards 5,687 4,541 Compensation 1,399 1,100 Allowances and reserves 457 1,007 State taxes 848 794 Credit carryforward 229 234 163(j) interest 141 - Leases 23 - Deferred revenue 88 89 Property, plant and equipment - 16 53,024 47,939 Deferred tax liability: Intangible assets 1,112 (44 ) Property, plant and equipment (263 ) - Valuation allowance (53,891 ) (47,895 ) Deferred tax liability-net valuation allowance $ (18 ) $ -
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows: 2019 2018 Federal statutory rate 21.0 % 21.0 % State income tax rate, net of Federal tax benefit 3.0 % 2.9 % Meals and entertainment (0.2 )% (0.3 )% Contingent consideration 0.0 % 0.0 % Tax reform change 0.0 % 0.0 % Valuation allowance (23.8 )% (23.7 )% Other non-deductible 0.0 % (0.1 )% Naked credit (0.1 )% 0.0 % Discontinued operations allocation 0.2 % 0.0 % Effective tax rate 0.1 % (0.2 )%
Schedule of Unrecognized Tax Benefits Roll Forward	The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2019: Unrecognized Tax Benefits Balance of unrecognized benefits as of January 1, 2018 $ 1,117 Reductions for tax positions of prior years (323 ) Balance as of December 31, 2018 $ 794 Additions for tax positions of prior years 54 Balance as of December 31, 2019 $ 848
Schedule of Tax Years Subject to Examination	The following tax years remain subject to examination as of December 31, 2019: Jurisdiction Tax Years Federal 2015 - 2019 State and Local 2014 - 2019

Historical Basic and Diluted _2

Historical Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares	A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2019 and 2018 is as follows (rounded to thousands): Years Ended December 31, 2019 2018 Basic weighted average number of common shares 3,746 2,815 Potential dilutive effect of stock-based awards - - Diluted weighted average number of common shares 3,746 2,815
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The Company’s Preferred Stock, on an as converted basis, and the following outstanding stock-based awards and warrants were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands): Years Ended December 31, 2019 2018 Options 416 283 Stock-settled stock appreciation rights (SARs) - 6 Restricted stock units (RSUs) 49 36 Warrants 1,420 1,354 1,885 1,679

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Disclosure of Cash flow Information	For The Years Ended December 31, 2019 2018 Net cash used in operating activities of discontinued operations $ (30 ) $ (361 ) Net cash provided by investing activities of discontinued operations $ - $ - Supplemental Disclosure of Other Cash Flow Information (in thousands) Cash paid for taxes $ 227 $ 324 Cash paid for interest $ 170 $ - Supplemental Disclosures of Non Cash Activities (in thousands) Years Ended December 31, 2019 2018 Operating Adoption of ASC 606 $ - $ 2,500 Prepaid stock grants issued to vendors $ - $ 497 Adoption of ASC 842 - right of use asset $ 2,449 $ - Adoption of ASC 842 - operating lease liability $ 2,536 $ - Financing Accrued financing costs $ 342 $ - Accrued preferred dividends $ 429 $ -

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule Ii - Valuation And Qualifying Accounts
Schedule of Valuation and Qualifying Accounts	Additions Balance at (Reductions) (1) Balance at Beginning Charged to Deductions end Description of Period Operations Other of Period 2018 (As Restated) Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance $ 46,308 - 1,587 $ 47,895 2019 (As Restated) Allowance for doubtful accounts $ - - 25 $ 25 Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance $ 47,895 - 5,996 $ 53,891 (1) Includes payments and actual write offs, as well as changes in estimates in the reserves.

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) $ in Thousands	Jan. 15, 2020	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jan. 02, 2019USD ($)
Number of reportable segments | Segment		1
Reduction of revenues		$ 3,500
Non-cash impairment charge					$ 12,000
Amortization expense		3,989	$ 3,589
Asset impairment					11,600
Barrett's and Thyroid Intangible Assets [Member]
Amortization expense		$ 340	$ 340	$ 340	$ 2,000	$ 2,300	$ 700
ASU Topic 606 [Member]
Cumulative catch-up adjustment under modified retrospective method								$ 2,500
Minimum [Member]
Finite-lived intangible asset, useful life		2 years
Maximum [Member]
Finite-lived intangible asset, useful life		9 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, plant and equipment, useful life		7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, plant and equipment, useful life		10 years
Office and Computer Equipment [Member] | Minimum [Member]
Property, plant and equipment, useful life		2 years
Office and Computer Equipment [Member] | Maximum [Member]
Property, plant and equipment, useful life		5 years
Lab Equipment [Member] | Minimum [Member]
Property, plant and equipment, useful life		3 years
Lab Equipment [Member] | Maximum [Member]
Property, plant and equipment, useful life		7 years
Leasehold Improvements [Member] | Minimum [Member]
Property, plant and equipment, useful life		4 years
Leasehold Improvements [Member] | Maximum [Member]
Property, plant and equipment, useful life		5 years
Software for Internal Use [Member] | Minimum [Member]
Property, plant and equipment, useful life		3 years
Software for Internal Use [Member] | Maximum [Member]
Property, plant and equipment, useful life		7 years
Software for External Use [Member]
Property, plant and equipment, useful life		3 years
Subsequent Event [Member]
Decreased issued and outstanding description	The Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the "Reverse Stock Split"). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company's issued and outstanding stock decreased from 39,205,895 to 3,920,589 and 28,694,275 to 2,869,427 at December 31, 2019 and 2018, respectively.

Nature of Business and Signif_5

Nature of Business and Significant Accounting Policies - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Indemnification assets		$ 875
Lab supply inventory	1,825
Prepaid assets	971	1,230
Funds in escrow	888
Other	167	65
Total other current assets	$ 3,851	$ 2,170

Nature of Business and Signif_6

Nature of Business and Significant Accounting Policies - Schedule of Misstatements of Assets (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended																												12 Months Ended
		Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Sep. 30, 2014		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Total Assets		$ 51,540				$ 31,127																								$ 51,540	$ 31,127	$ 36,619		$ 25,136		$ 64,741		$ 115,211
Assets Amortization																																(5,347)		(5,010)		(2,971)		(695)
Assets Impairment																																(11,632)		(11,632)
Assets Other		167				65																								167	65
Stockholders' Equity		(4,479)	$ 6,030	$ 13,346	$ 18,372	15,446	$ 18,799	$ 21,406	$ 22,703	$ 19,484		$ 19,532		$ 7,843		$ (5,979)		$ 2,003		$ 4,826		$ 3,400		$ 8,347		$ 15,183		$ 25,306		(4,479)	15,446	22,891		(10,111)		10,067		19,427
Stockholders' Equity Amortization																																(5,347)		(5,010)		(2,971)		(695)
Stockholders' Equity Impairment																																(11,632)		(11,632)
Stockholders' Equity Other
Net Loss		(10,663)	$ (7,446)	$ (5,304)	$ (3,326)	(4,299)	$ (3,126)	$ (2,001)	$ (3,277)	$ (3,400)		$ (6,390)		$ 2,330		$ (8,003)		$ (2,844)		$ (5,296)		$ (5,405)		$ (7,488)		$ (4,614)		$ (4,454)		$ (26,740)	$ (12,703)	12,553		(22,003)		(13,623)		(16,768)
Net Loss Amortization																																(337)		(2,039)		(2,276)		(695)
Net Loss Impairment																																		(11,632)
Net Loss Other
Earnings Per Share										$ (1.54)	[1]	$ (6.61)	[1]	$ 5.32	[1]	$ (43.97)	[1]	$ (15.63)	[1]	$ (29.75)	[1]	$ (34.43)	[1]	$ (49.26)	[1]	$ (30.76)	[1]	$ (29.89)	[1]	$ (7.25)	$ (4.52)	$ (7.96)	[1]	$ (120.90)	[1]	$ (87.95)	[1]	$ (112.53)	[1]
Earnings Per Share Amortization	[1]																															(0.21)		(11.20)		(14.68)		(4.66)
Earnings Per Share Impairment	[1]																																	(63.91)
Earnings Per Share Other	[1]
As Previously Reported [Member]
Total Assets		69,051				48,442																								$ 69,051	$ 48,442	$ 53,598		$ 41,778		$ 67,712		$ 115,906
Stockholders' Equity		$ 13,026				$ 32,938				$ 36,378		$ 36,342		$ 24,569		$ (1,479)		$ 5,993		$ 8,306		$ 5,861		$ 10,298		$ 16,624		$ 25,424		13,026	32,938	39,869		6,531		13,038		20,122
Net Loss										$ (3,316)		$ (6,306)		$ 2,414		$ (7,493)		$ (2,334)		$ (4,786)		$ (4,895)		$ (6,978)		$ (3,868)		$ (4,336)		$ (26,727)	$ (12,189)	$ (12,216)		$ (8,332)		$ (11,356)		$ (16,073)
Earnings Per Share										$ (1.51)	[1]	$ (6.53)	[1]	$ 5.51	[1]	$ (41.17)	[1]	$ (12.82)	[1]	$ (26.89)	[1]	$ (31.18)	[1]	$ (45.91)	[1]	$ (25.79)	[1]	$ (29.10)	[1]	$ (7.25)	$ (4.33)	$ (7.75)	[1]	$ (45.78)	[1]	$ (73.26)	[1]	$ (107.87)	[1]
[1]	Adjusted for reverse stock splits since the filing of the original financial statements.

Nature of Business and Signif_7

Nature of Business and Significant Accounting Policies - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																												12 Months Ended										36 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Sep. 30, 2014		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Cash and cash equivalents																																								$ 2,321	$ 6,068
Accounts receivable, net																																								10,338	9,483
Other current assets																																								3,851	2,170
Total current assets																																								16,510	17,721
Property and equipment, net																																								6,814	837
Other intangible assets, net																																								15,849	12,538
Goodwill																																								8,433
Operating lease right of use assets																																								3,892
Other long-term assets																																								42	31
Total assets																																								51,540	31,127	36,619				$ 25,136				$ 64,741				$ 115,211
Accounts payable																																								4,709	1,059
Accrued salary and bonus																																								2,341	1,544
Other accrued expenses																																								9,476	5,148
Current liabilities from discontinued operations																																								766	918
Total current liabilities																																								17,292	8,669
Contingent consideration																																								2,391	2,693
Operating lease liabilities, net of current portion																																								2,591
Line of credit																																								3,000
Other long-term liabilities																																								4,573	4,319
Total liabilities																																								29,847	15,681
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding																																								26,172
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;																																								393	287
Additional paid-in capital																																								182,514	175,820
Accumulated deficit																																								(185,665)	(158,981)
Treasury stock, at cost (11,781 shares)																																								(1,721)	(1,680)
Total stockholders' equity	$ 6,030	$ 13,346	$ 13,346	$ 18,372	$ 18,799	$ 21,406	$ 21,406	$ 22,703	$ 19,484		$ 19,532		$ 7,843		$ (5,979)		$ 2,003		$ 4,826		$ 3,400		$ 8,347		$ 15,183		$ 25,306		$ (4,479)	$ 22,891	$ (10,111)		$ (10,111)		$ 10,067		$ 19,427		$ (10,111)	(4,479)	15,446	22,891	19,484	19,532	7,843	(10,111)	(5,979)	2,003	4,826	10,067	3,400	8,347	15,183	19,427	25,306
Total liabilities and stockholders' equity																																								25,368	31,127
Total liabilities, preferred stock and stockholders' equity																																								51,540	31,127
Revenue, net																													24,220	21,896
Cost of revenue																													15,888	10,197
Gross profit																													8,332	11,699
Sales and marketing																													11,116	8,421
Research and development																													2,810	2,124
General and administrative																													14,363	8,676
Acquisition related expense																													2,534
Acquisition related amortization expense																													3,989	3,589
Change in fair value of contingent consideration																													(44)	1,522
Total operating expenses																													34,768	24,332
Operating loss																													(26,436)	(12,633)
Accretion expense																													(440)	(331)
Other income (expense), net																													196	263
Loss from continuing operations before tax																													(26,680)	(12,701)
(Benefit) provision for income taxes																													(28)	18
Loss from continuing operations																													(26,652)	(12,719)
Income from discontinued operations, net of tax																													(88)	16
Net loss	(10,663)	(7,446)	(5,304)	(3,326)	(4,299)	(3,126)	(2,001)	(3,277)	$ (3,400)		$ (6,390)		$ 2,330		$ (8,003)		$ (2,844)		$ (5,296)		$ (5,405)		$ (7,488)		$ (4,614)		$ (4,454)		(26,740)	(12,703)	$ 12,553		$ (22,003)		$ (13,623)		$ (16,768)
Less dividends on preferred stock																													(429)
Net loss attributable to common stockholders																													$ (27,169)	$ (12,703)
From continuing operations																													$ (7.23)	$ (4.52)
From discontinued operations																													(0.02)
Net loss per basic and diluted share of common stock									$ (1.54)	[1]	$ (6.61)	[1]	$ 5.32	[1]	$ (43.97)	[1]	$ (15.63)	[1]	$ (29.75)	[1]	$ (34.43)	[1]	$ (49.26)	[1]	$ (30.76)	[1]	$ (29.89)	[1]	$ (7.25)	$ (4.52)	$ (7.96)	[1]	$ (120.90)	[1]	$ (87.95)	[1]	$ (112.53)	[1]
Balance	6,030	13,346	18,372	15,446	18,799	21,406	22,703	22,891	$ 19,532		$ 7,843		$ (10,111)		$ 2,003		$ 4,826		$ 10,067		$ 8,347		$ 15,183		$ 19,427				$ 15,446	$ 22,891	$ (10,111)		$ 10,067		$ 19,427				(10,111)
Common stock issued			73	1	594	143	285	1
Common stock issued through offering, net of expenses				5,962
Common stock issued through market sales, net of expenses	228
Treasury stock purchased	(9)			(32)				(9)
Stock-based compensation expense	289	205	205	266	352		419	597
Dividends accrued	(354)	(75)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(4,479)	6,030	13,346	18,372	15,446	18,799	21,406	22,703	19,484		19,532		7,843		(5,979)		2,003		4,826		3,400		8,347		15,183		$ 25,306		(4,479)	15,446	22,891		(10,111)		10,067		$ 19,427		(4,479)
Depreciation and amortization																													4,524	3,801
Interest accretion																													440	331
Bad debt expense																													499
Reversal of DOJ accrual																														(350)
Mark to market on warrants																													(279)	112
Stock-based compensation																													1,535	2,270
Deferred income taxes																													18
Change in estimate on collectability of accounts receivable																													3,479
Other gains and expenses, net																													18
Increase in accounts receivable																													(1,102)	(3,546)
Decrease (increase) in other current assets																													129	(501)
Increase in other long-term assets																													(11)
(Decrease) increase in accounts payable																													(938)	668
Increase in accrued salaries and bonus																													362	150
Decrease in accrued liabilities																													(1,301)	(345)
Increase (decrease) in long-term liabilities																													454	(82)
Net cash used in operating activities																													(18,957)	(8,673)
Acquisition of Biopharma, net of cash acquired																													(13,829)
Purchase of property and equipment																													(131)	(449)
Sale of property and equipment																													13
Net cash used in investing activity																													(13,947)	(449)
Issuance of common stock, net of expenses																													6,478
Issuance of preferred stock, net of expenses																													25,744
Payment of CGIX note and related interest																													6,024
Borrowings on Line of Credit																													3,000
Cash paid for repurchase of restricted shares																													(41)	(9)
Net cash provided by (used in) financing activities																													29,157	(9)
Net decrease in cash and cash equivalents																													(3,747)	(9,131)
Cash and cash equivalents - beginning of year				6,068				15,199																					6,068	15,199
Cash and cash equivalents - end of year	2,321				6,068																								2,321	6,068	15,199								2,321
Common Stock [Member]
Total stockholders' equity	393	383	383	382	287	283	282	279																					393	287	278								$ 393	393	287	278
Net loss
Balance	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279	$ 278																					$ 287	$ 278
Balance, shares	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000	2,790,000																					2,877,000	2,790,000
Common stock issued			$ 1	$ 1	$ 4	$ 1	$ 3	$ 1
Common stock issued, shares	5,000		10,000	9,000	40,000	10,000	33,000	4,000																															3,700,000
Common stock issued through offering, net of expenses				$ 94
Common stock issued through offering, net of expenses, shares				933,000
Common stock issued through market sales, net of expenses	$ 10
Common stock issued through market sales, net of expenses, shares	98,000
Balance	$ 393	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279																					$ 393	$ 287	$ 278								$ 393
Balance, shares	3,932,000	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000																					3,932,000	2,877,000	2,790,000								3,932,000
Treasury Stock [Member]
Total stockholders' equity	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)	(1,721)	(1,680)	(1,671)
Net loss
Balance	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,680)	$ (1,671)
Balance, shares	10,000	10,000	10,000	7,000	7,000	7,000	7,000	6,000																					7,000	6,000
Treasury stock purchased	$ (9)			$ (32)				$ (9)
Treasury stock purchased, shares	2,000			3,000				1,000
Balance	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)
Balance, shares	12,000	10,000	10,000	10,000	7,000	7,000	7,000	7,000																					12,000	7,000	6,000								12,000
Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,514	$ 182,231	$ 182,231	$ 181,954	$ 175,820	$ 174,878	$ 174,360	$ 173,659																					$ 182,514	$ 175,820	$ 173,062								$ 182,514	182,514	175,820	173,062
Balance	182,361	182,231	181,954	175,820	174,878	174,360	173,659	173,062																					175,820	173,062
Common stock issued			72		598	144	282
Common stock issued through offering, net of expenses				5,868
Common stock issued through market sales, net of expenses	218
Stock-based compensation expense	289	205	205	266	344	374	419	597
Dividends accrued	(354)	(75)
Balance	182,514	182,361	182,231	181,954	175,820	174,878	174,360	173,659																					182,514	175,820	173,062								182,514
Accumulated Deficit [Member]
Total stockholders' equity	(185,665)	(167,556)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)																					(185,665)	(158,981)	(148,778)								(185,665)	(185,665)	(158,981)	(148,778)
Net loss	(10,663)	(7,446)	(5,304)	(3,326)	(4,299)	(3,126)	(2,001)	(3,277)
Balance	(175,002)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)	(148,778)																					(158,981)	(148,778)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(185,665)	(175,002)	(167,556)	(162,252)	(158,981)	(154,682)	(151,556)	(149,555)																					(185,665)	(158,981)	(148,778)								(185,665)
As Previously Reported [Member]
Cash and cash equivalents																																								2,321	6,068
Accounts receivable, net																																								10,197	9,483
Other current assets																																								3,851	2,170
Total current assets																																								16,369	17,721
Property and equipment, net																																								6,814	837
Other intangible assets, net																																								33,501	29,853
Goodwill																																								8,433
Operating lease right of use assets																																								3,892
Other long-term assets																																								42	31
Total assets																																								69,051	48,442	53,598				41,778				67,712				115,906
Accounts payable																																								4,812	1,059
Accrued salary and bonus																																								2,341	1,424
Other accrued expenses																																								9,379	5,091
Current liabilities from discontinued operations																																								766	918
Total current liabilities																																								17,298	8,492
Contingent consideration																																								2,391	2,693
Operating lease liabilities, net of current portion																																								2,591
Line of credit																																								3,000
Other long-term liabilities																																								4,573	4,319
Total liabilities																																								29,853	15,504
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding																																								29,853
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;																																								393	287
Additional paid-in capital																																								182,514	175,820
Accumulated deficit																																								(168,160)	(141,489)
Treasury stock, at cost (11,781 shares)																																								(1,721)	(1,680)
Total stockholders' equity	13,026			32,938	32,938			39,869	36,378		36,342		24,569		(1,479)		5,993		8,306		5,861		10,298		16,624		25,424		32,938	39,869	6,531		6,531		13,038		20,122		6,531	13,026	32,938	39,869	$ 36,378	$ 36,342	$ 24,569	$ 6,531	$ (1,479)	$ 5,993	$ 8,306	$ 13,038	$ 5,861	$ 10,298	$ 16,624	$ 20,122	$ 25,424
Total liabilities and stockholders' equity																																								42,879
Total liabilities, preferred stock and stockholders' equity																																								69,051	48,442
Revenue, net																													24,079	21,896
Cost of revenue																													15,888	10,197
Gross profit																													8,191	11,699
Sales and marketing																													11,116	8,421
Research and development																													2,810	2,124
General and administrative																													14,546	8,499
Acquisition related expense																													2,534
Acquisition related amortization expense																													3,652	3,252
Change in fair value of contingent consideration																													(44)	1,522
Total operating expenses																													34,614	23,818
Operating loss																													(26,423)	(12,119)
Accretion expense																													(440)	(331)
Other income (expense), net																													196	263
Loss from continuing operations before tax																													(26,667)	(12,187)
(Benefit) provision for income taxes																													(28)	18
Loss from continuing operations																													(26,639)	(12,205)
Income from discontinued operations, net of tax																													(88)	16
Net loss									$ (3,316)		$ (6,306)		$ 2,414		$ (7,493)		$ (2,334)		$ (4,786)		$ (4,895)		$ (6,978)		$ (3,868)		$ (4,336)		(26,727)	$ (12,189)	$ (12,216)		$ (8,332)		$ (11,356)		$ (16,073)
Less dividends on preferred stock																													(429)
Net loss attributable to common stockholders																													$ (27,156)
From continuing operations																													$ (7.23)	$ (4.33)
From discontinued operations																													(0.02)
Net loss per basic and diluted share of common stock									$ (1.51)	[1]	$ (6.53)	[1]	$ 5.51	[1]	$ (41.17)	[1]	$ (12.82)	[1]	$ (26.89)	[1]	$ (31.18)	[1]	$ (45.91)	[1]	$ (25.79)	[1]	$ (29.10)	[1]	$ (7.25)	$ (4.33)	$ (7.75)	[1]	$ (45.78)	[1]	$ (73.26)	[1]	$ (107.87)	[1]
Balance				32,938				39,869	$ 36,342		$ 24,569		$ 6,531		$ 5,993		$ 8,306		$ 13,038		$ 10,298		$ 16,624		$ 20,122				$ 32,938	$ 39,869	$ 6,531		$ 13,038		$ 20,122				6,531
Balance	13,026				32,938				$ 36,378		$ 36,342		$ 24,569		$ (1,479)		$ 5,993		$ 8,306		$ 5,861		$ 10,298		$ 16,624		$ 25,424		13,026	32,938	39,869		$ 6,531		$ 13,038		$ 20,122		13,026
Depreciation and amortization																													4,187	3,464
Interest accretion																													440	331
Bad debt expense																													499
Reversal of DOJ accrual																														(350)
Mark to market on warrants																													(279)	112
Stock-based compensation																													1,535	2,270
Deferred income taxes																													18
Change in estimate on collectability of accounts receivable																													3,479
Other gains and expenses, net																													18
Increase in accounts receivable																													(961)	(3,546)
Decrease (increase) in other current assets																													129	(501)
Increase in other long-term assets																													(11)
(Decrease) increase in accounts payable																													(835)	668
Increase in accrued salaries and bonus																													482	30
Decrease in accrued liabilities																													(1,341)	(402)
Increase (decrease) in long-term liabilities																													454	(82)
Net cash used in operating activities																													(18,957)	(8,673)
Acquisition of Biopharma, net of cash acquired																													(13,829)
Purchase of property and equipment																													(131)	(449)
Sale of property and equipment																													13
Net cash used in investing activity																													(13,947)	(449)
Issuance of common stock, net of expenses																													6,478
Issuance of preferred stock, net of expenses																													25,744
Payment of CGIX note and related interest																													(6,024)
Borrowings on Line of Credit																													3,000
Cash paid for repurchase of restricted shares																													(41)	(9)
Net cash provided by (used in) financing activities																													29,157	(9)
Net decrease in cash and cash equivalents																													(3,747)	(9,131)
Cash and cash equivalents - beginning of year				6,068				15,199																					6,068	15,199
Cash and cash equivalents - end of year	2,321				6,068																								2,321	6,068	15,199								2,321
As Previously Reported [Member] | Common Stock [Member]
Total stockholders' equity	393	383	383	382	283	283	282	279																					393	278	278								393	393	287	278
Balance	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279	$ 278																					$ 287	$ 278
Balance, shares	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000	2,790,000																					2,877,000	2,790,000
Common stock issued			$ 1	$ 1	$ 4	$ 1	$ 3	$ 1
Common stock issued, shares	5,000		10,000	9,000	40,000	10,000	33,000	4,000
Common stock issued through offering, net of expenses				$ 94
Common stock issued through offering, net of expenses, shares				933,000
Common stock issued through market sales, net of expenses	$ 10
Common stock issued through market sales, net of expenses, shares	98,000
Balance	$ 393	$ 383	$ 383	$ 382	$ 287	$ 283	$ 282	$ 279																					$ 393	$ 287	$ 278								$ 393
Balance, shares	3,932,000	3,829,000	3,829,000	3,819,000	2,877,000	2,837,000	2,827,000	2,794,000																					3,932,000	2,877,000	2,790,000								3,932,000
As Previously Reported [Member] | Treasury Stock [Member]
Total stockholders' equity	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,721)	$ (1,671)	$ (1,671)								$ (1,721)	(1,721)	(1,680)	(1,671)
Balance	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,671)																					$ (1,680)	$ (1,671)
Balance, shares	10,000	10,000	10,000	7,000	7,000	7,000	7,000	6,000																					7,000	6,000
Treasury stock purchased	$ (9)			$ (32)				$ (9)
Treasury stock purchased, shares	2,000			3,000				1,000
Balance	$ (1,721)	$ (1,712)	$ (1,712)	$ (1,712)	$ (1,680)	$ (1,680)	$ (1,680)	$ (1,680)																					$ (1,721)	$ (1,680)	$ (1,671)								$ (1,721)
Balance, shares	12,000	10,000	10,000	10,000	7,000	7,000	7,000	7,000																					12,000	7,000	6,000								12,000
As Previously Reported [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity	$ 182,514	$ 182,361	$ 182,231	$ 181,954	$ 174,878	$ 174,878	$ 174,360	$ 173,659																					$ 182,514	$ 173,062	$ 173,062								$ 182,514	182,514	175,820	173,062
Balance	182,361	182,231	181,954	175,820	174,878	174,360	173,659	$ 173,062																					175,820	173,062
Common stock issued			72		598	144	282
Common stock issued through offering, net of expenses				5,868
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses	218
Stock-based compensation expense	289	205	205	266	344	374	419	$ 597
Dividends accrued	(354)	(75)
Balance	182,514	182,361	182,231	181,954	175,820	174,878	174,360	173,659																					182,514	175,820	173,062								182,514
As Previously Reported [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(168,160)	(157,435)	(150,073)	(144,853)	(137,452)	(137,452)	(134,410)	(132,493)																					(168,160)	(131,800)	(131,800)								(168,160)	(168,160)	(141,489)	(131,800)
Net loss	(10,725)	(7,362)	(5,220)	(3,419)	(4,037)	(3,042)	(1,917)	(3,193)
Balance	(157,435)	(150,073)	(144,853)	(141,489)	(137,452)	(134,410)	(132,493)	(131,800)																					(141,489)	(131,800)
Adoption of ASC 606								2,500
Adoption of ASC 842				55
Balance	(168,160)	(157,435)	(150,073)	(144,853)	(141,489)	(137,452)	(134,410)	(132,493)																					(168,160)	(141,489)	(131,800)								(168,160)
Restatement Amount [Member]
Cash and cash equivalents
Accounts receivable, net																																								141
Other current assets
Total current assets																																								141
Property and equipment, net
Other intangible assets, net																																								(17,652)	(17,315)
Goodwill
Operating lease right of use assets
Other long-term assets
Total assets																																								(17,511)	(17,315)
Accounts payable																																								(103)
Accrued salary and bonus																																									120
Other accrued expenses																																								97	57
Current liabilities from discontinued operations
Total current liabilities																																								(6)	177
Contingent consideration
Operating lease liabilities, net of current portion
Line of credit
Other long-term liabilities
Total liabilities																																								(6)	177
Preferred stock, $.01 par value; 5,000,000 shares authorized, 270 shares issued and outstanding
Common stock, $.01 par value; 100,000,000 shares authorized; 3,932,370 shares issued and 3,920,589 shares outstanding;
Additional paid-in capital
Accumulated deficit																																								(17,505)	(17,492)
Treasury stock, at cost (11,781 shares)
Total stockholders' equity	(17,505)			(17,492)	(17,492)																								(17,505)	(17,492)									(17,505)	(17,505)	(17,492)
Total liabilities and stockholders' equity																																								(17,511)
Total liabilities, preferred stock and stockholders' equity																																								(17,511)	(17,315)
Revenue, net																													141
Cost of revenue
Gross profit																													141
Sales and marketing
Research and development
General and administrative																													(183)	177
Acquisition related expense
Acquisition related amortization expense																													337	337
Change in fair value of contingent consideration
Total operating expenses																													154	514
Operating loss																													(13)	(514)
Accretion expense
Other income (expense), net
Loss from continuing operations before tax																													(13)	(514)
(Benefit) provision for income taxes
Loss from continuing operations																													(13)	(514)
Income from discontinued operations, net of tax
Net loss																													(13)	$ (514)
Less dividends on preferred stock
Net loss attributable to common stockholders																													$ (13)
From continuing operations																													$ 0	$ (0.19)
From discontinued operations
Net loss per basic and diluted share of common stock																													$ 0	$ (0.19)
Balance				(17,492)																									$ (17,492)
Balance	(17,505)				(17,492)																								(17,505)	$ (17,492)									(17,505)
Depreciation and amortization																													337	337
Interest accretion
Bad debt expense
Reversal of DOJ accrual
Mark to market on warrants
Stock-based compensation
Deferred income taxes
Change in estimate on collectability of accounts receivable
Other gains and expenses, net
Increase in accounts receivable																													(141)
Decrease (increase) in other current assets
Increase in other long-term assets
(Decrease) increase in accounts payable																													(103)
Increase in accrued salaries and bonus																													(120)	120
Decrease in accrued liabilities																													40	57
Increase (decrease) in long-term liabilities
Net cash used in operating activities
Acquisition of Biopharma, net of cash acquired
Purchase of property and equipment
Sale of property and equipment
Net cash used in investing activity
Issuance of common stock, net of expenses
Issuance of preferred stock, net of expenses
Payment of CGIX note and related interest
Borrowings on Line of Credit
Cash paid for repurchase of restricted shares
Net cash provided by (used in) financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents - beginning of year
Cash and cash equivalents - end of year
Restatement Amount [Member] | Common Stock [Member]
Total stockholders' equity
Balance
Balance, shares
Common stock issued
Common stock issued, shares
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses
Common stock issued through market sales, net of expenses, shares
Balance
Balance, shares
Restatement Amount [Member] | Treasury Stock [Member]
Total stockholders' equity
Balance
Balance, shares
Treasury stock purchased
Treasury stock purchased, shares
Balance
Balance, shares
Restatement Amount [Member] | Additional Paid-in Capital [Member]
Total stockholders' equity
Balance
Common stock issued
Common stock issued through offering, net of expenses
Common stock issued through offering, net of expenses, shares
Common stock issued through market sales, net of expenses
Stock-based compensation expense
Dividends accrued
Balance
Restatement Amount [Member] | Accumulated Deficit [Member]
Total stockholders' equity	(17,505)	(17,567)	(17,483)	(17,399)	(17,230)	(17,230)	(17,146)	(17,062)																					(17,505)	(16,978)	(16,978)								(17,505)	$ (17,505)	$ (17,492)	$ (16,978)
Net loss	62	(84)	(84)	93	(262)	(84)	(84)	(84)
Balance	(17,567)	(17,483)	(17,399)	(17,492)	(17,230)	(17,146)	(17,062)	(16,978)																					(17,492)	(16,978)
Adoption of ASC 606
Adoption of ASC 842
Balance	$ (17,505)	$ (17,567)	$ (17,483)	$ (17,399)	$ (17,492)	$ (17,230)	$ (17,146)	$ (17,062)																					$ (17,505)	$ (17,492)	$ (16,978)								$ (17,505)
[1]	Adjusted for reverse stock splits since the filing of the original financial statements.

Nature of Business and Signif_8

Nature of Business and Significant Accounting Policies - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details) (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	270	270
Preferred stock, shares outstanding	270	270
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,932,370	2,876,734
Common stock, shares outstanding	3,920,589	2,869,427
Treasury stock, shares	11,781	7,307
As Previously Reported [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	270	270
Preferred stock, shares outstanding	270	270
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,932,370	2,876,734
Common stock, shares outstanding	3,920,589	2,869,427
Treasury stock, shares	11,781	7,307
Restatement Amount [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	270	270
Preferred stock, shares outstanding	270	270
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,932,370	2,876,734
Common stock, shares outstanding	3,920,589	2,869,427
Treasury stock, shares	11,781	7,307

Nature of Business and Signif_9

Nature of Business and Significant Accounting Policies - Schedule of Materially Impacted by the Restatement (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended																												12 Months Ended
		Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Sep. 30, 2014		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Total Assets										$ 33,497		$ 36,934		$ 30,249		$ 41,464		$ 49,520		$ 53,295		$ 96,826		$ 105,622		$ 111,171		$ 62,109
Asset Amortization										(5,262)		(5,178)		(5,094)		(4,500)		(3,990)		(3,480)		(2,461)		(1,951)		(1,441)		(118)		$ (4,000)	$ (3,600)
Asset Impairment										(11,632)		(11,632)		(11,632)
Other		$ 15,849				$ 12,538																								15,849	12,538
Stockholders' Equity		(4,479)	$ 6,030	$ 13,346	$ 18,372	15,446	$ 18,799	$ 21,406	$ 22,703	19,484		19,532		7,843		(5,979)		2,003		4,826		3,400		8,347		15,183		25,306		(4,479)	15,446	$ 22,891		$ (10,111)		$ 10,067		$ 19,427
Net Income (Loss)		(10,663)	$ (7,446)	$ (5,304)	$ (3,326)	(4,299)	$ (3,126)	$ (2,001)	$ (3,277)	$ (3,400)		$ (6,390)		$ 2,330		$ (8,003)		$ (2,844)		$ (5,296)		$ (5,405)		$ (7,488)		$ (4,614)		$ (4,454)		$ (26,740)	$ (12,703)	$ 12,553		$ (22,003)		$ (13,623)		$ (16,768)
Earnings Per Share										$ (1.54)	[1]	$ (6.61)	[1]	$ 5.32	[1]	$ (43.97)	[1]	$ (15.63)	[1]	$ (29.75)	[1]	$ (34.43)	[1]	$ (49.26)	[1]	$ (30.76)	[1]	$ (29.89)	[1]	$ (7.25)	$ (4.52)	$ (7.96)	[1]	$ (120.90)	[1]	$ (87.95)	[1]	$ (112.53)	[1]
As Previously Reported [Member]
Total Assets										$ 50,391		$ 53,744		$ 46,975		$ 45,964		$ 53,510		$ 56,775		$ 99,287		$ 107,573		$ 112,612		$ 62,227
Other		33,501				29,853																								$ 33,501	$ 29,853
Stockholders' Equity		$ 13,026				$ 32,938				36,378		36,342		24,569		(1,479)		5,993		8,306		5,861		10,298		16,624		25,424		13,026	32,938	$ 39,869		$ 6,531		$ 13,038		$ 20,122
Net Income (Loss)										$ (3,316)		$ (6,306)		$ 2,414		$ (7,493)		$ (2,334)		$ (4,786)		$ (4,895)		$ (6,978)		$ (3,868)		$ (4,336)		$ (26,727)	$ (12,189)	$ (12,216)		$ (8,332)		$ (11,356)		$ (16,073)
Earnings Per Share										$ (1.51)	[1]	$ (6.53)	[1]	$ 5.51	[1]	$ (41.17)	[1]	$ (12.82)	[1]	$ (26.89)	[1]	$ (31.18)	[1]	$ (45.91)	[1]	$ (25.79)	[1]	$ (29.10)	[1]	$ (7.25)	$ (4.33)	$ (7.75)	[1]	$ (45.78)	[1]	$ (73.26)	[1]	$ (107.87)	[1]
Asset Amortization [Member]
Stockholders' Equity										$ (5,262)		$ (5,178)		$ (5,094)		$ (4,500)		$ (3,990)		$ (3,480)		$ (2,461)		$ (1,951)		$ (1,441)		$ (118)
Net Income (Loss)										$ (84)		$ (84)		$ (84)		$ (510)		$ (510)		$ (510)		$ (510)		$ (510)		$ (746)		$ (118)
Earnings Per Share	[1]									$ (0.04)		$ (0.09)		$ (0.19)		$ (2.80)		$ (2.80)		$ (2.87)		$ (3.25)		$ (3.36)		$ (4.97)		$ (0.79)
Asset Impairment [Member]
Stockholders' Equity										$ (11,632)		$ (11,632)		$ (11,632)
Net Income (Loss)
Earnings Per Share	[1]
Other [Member]
Total Assets
Stockholders' Equity
Net Income (Loss)
Earnings Per Share	[1]
[1]	Adjusted for reverse stock splits since the filing of the original financial statements.

Acquisition (Details Narrative)

Acquisition (Details Narrative) - USD ($)	Oct. 18, 2019	Jul. 15, 2019	Jun. 30, 2019	Dec. 31, 2019	Apr. 21, 2020
Cliam offset amoount				$ 735,000
Expiration period of cliam				Jan. 15, 2020
Payment settlement	$ 6,024,489
Indemnification holdback description				Any amounts due to the Company under the NWA were to be set off against the Excess Consideration Note and any amounts due to the Company under the ARA were to be either set off against the Excess Consideration Note or, if it is no longer outstanding, satisfied through an AR Holdback (as defined in the Asset Purchase Agreement) mechanism, in each case as further set forth in the Asset Purchase Agreement. Additionally, an indemnification holdback of $735,000 was established as an offset for any potential claims against the Company related to the transaction. The expiration period for the notification of any third-party claims was set at January 15, 2020. On October 18, 2019, a payment of $6,024,489 was made in settlement of the note less remaining holdbacks of $887,858, $735,000 for the Indemnification Holdback and $152,858 for the remaining AR Holdback. In March 2020, the Company reimbursed CGI for the full amount of the $887,858 holdbacks after its determination that the contractual obligations related to the holdbacks had been fully satisfied.
Repayments of debt	887,858
Goodwills		$ 8,300,000		$ 8,433,000
Finite lived intangible assets		$ 7,300,000
Finite lived intangible assets weighted-average amortization period		8 years 4 months 24 days
Business transaction expenses		$ 2,500,000
Trademarks [Member]
Finite lived intangible assets weighted-average amortization period		10 years
Customer Relationships [Member]
Finite lived intangible assets weighted-average amortization period		8 years
Subsequent Event [Member]
Reimbursements amount					$ 735,000
Indemnification Holdback [Member]
Repayments of debt	735,000
AR Holdback [Member]
Repayments of debt	$ 152,858
CGI Bio Pharma [Member]
Business combination consideration amount			$ 775,000
Accounts receivable				$ 830,000
Asset Purchase Agreement [Member] | Inital Tranche [Member]
Payment of preferred stock financing		$ 13,800,000
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]
Assets and assumed certain liabilities		23,500,000
Proceeds from debt		7,692,300
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member] | Base Purchase Price [Member]
Assets and assumed certain liabilities		$ 1,980,000

Acquisition - Schedule of Asset

Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Jul. 15, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	$ 7,300,000
Goodwill		$ 8,433,000
BioPharma Acquisition [Member]
Business Acquisition [Line Items]
Cash	13,829,000
Subordinated note payable	6,822,000
Total consideration	20,651,000
Accounts receivable	3,731,000
Accrued revenue	289,000
Lab supplies	877,000
Prepaid expenses	266,000
Property and equipment	6,412,000
Operating lease assets	2,187,000
Total acquired identifiable intangible assets	7,300,000
Goodwill	8,273,000
Total assets acquired	29,335,000
Accounts payable	(4,535,000)
Accrued liabilities	(435,000)
Deferred revenue	(1,076,000)
Operating lease liabilities	(2,187,000)
Finance lease liabilities	(451,000)
Total liabilities assumed	(8,684,000)
Net assets acquired	20,651,000
BioPharma Acquisition [Member] | Trademarks and Trade Name [Member]
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	1,600,000
BioPharma Acquisition [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	$ 5,700,000

Acquisition - Schedule of ProFo

Acquisition - Schedule of ProForma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Revenue	$ 31,722	$ 37,218

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($) $ in Thousands	Apr. 21, 2020	Jan. 31, 2020	Sep. 30, 2019	Nov. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 20, 2020	Mar. 31, 2020	Nov. 30, 2019	Jul. 31, 2019
Cash and cash equivalents					$ 2,321				$ 6,068														$ 2,321	$ 6,068
Accounts receivable, net					10,338				9,483														10,338	9,483
Total current assets					16,510				17,721														16,510	17,721
Total current liabilities					17,292				8,669														17,292	8,669
Net loss					10,663	$ 7,446	$ 5,304	$ 3,326	4,299	$ 3,126	$ 2,001	$ 3,277	$ 3,400	$ 6,390	$ (2,330)	$ 8,003	$ 2,844	$ 5,296	$ 5,405	$ 7,488	$ 4,614	$ 4,454	26,740	12,703	$ (12,553)	$ 22,003	$ 13,623	$ 16,768
Net cash used in operating activities																							18,957	8,673
Line of credit facility					3,000																		3,000
Public offering generating net proceeds																							$ 200
Sale of common stock																							97,817
Stockholder's equity increased			$ 6,030		(4,479)	$ 6,030	$ 13,346	$ 18,372	$ 15,446	$ 18,799	$ 21,406	$ 22,703	$ 19,484	$ 19,532	$ 7,843	$ (5,979)	$ 2,003	$ 4,826	$ 3,400	$ 8,347	$ 15,183	$ 25,306	$ (4,479)	$ 15,446	$ 22,891	$ (10,111)	$ 10,067	$ 19,427
Silicon Valley Bank [Member]
Line of credit facility				$ 850	$ 3,000																		$ 3,000
Line of credit facility term loan				3 years
Line of credit facility, description				The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.																			The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021
Line of credit, percentage				0.50%
Silicon Valley Bank [Member] | Prime Rate [Member]
Line of credit, percentage				5.00%																			0.50%
Silicon Valley Bank [Member] | Maximum [Member]
Line of credit facility																															$ 4,000
Subsequent Event [Member]
Line of credit facility																														$ 350
Stockholder's equity increased		$ 47,000
Description for loans to qualifying businesses value and its term	As of April 20, 2020, the Company's PPP loan has not yet been approved, pending new legislation increasing the pool. The PPP provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. If the Company is successful in obtaining a PPP loan, we intend to use the proceeds for purposes consistent with the PPP and expect to meet the conditions for forgiveness of the loan.
Cash	$ 18,400
Subsequent Event [Member] | Credit Facility [Member]
Cash																													$ 3,400
Subsequent Event [Member] | Maximum [Member] | Credit Facility [Member]
Cash	8,000																												8,000
Subsequent Event [Member] | Minimum [Member] | Credit Facility [Member]
Cash	4,000																												4,000
Subsequent Event [Member] | Preferred Stock [Member]
Public offering generating net proceeds		$ 19,500
Sale of common stock		20,000
Security Purchase and Exchange Agreement [Member]
Line of credit facility																																$ 4,000
Equity Distribution Agreement [Member]
Public offering generating net proceeds			$ 4,800
ATM Agreement [Member]
Public offering generating net proceeds																							$ 8,000
Small Business Administration [Member] | Subsequent Event [Member]
Loans payable																													3,500
Department of Health and Human Services [Member] | Subsequent Event [Member]
Loans payable																													650
Proceeds from loans payable	650
Centers for Medicare & Medicaid Services [Member] | Subsequent Event [Member]
Loans payable																													$ 2,100
Proceeds from loans payable	$ 2,100

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Accounts payable		$ 192
Accrued liabilities	766	726
Current liabilities from discontinued operations	766	918
Total liabilities	$ 766	$ 918

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Warrant liability	$ 82	$ 361
Fair value of liabilities	2,975	3,488
Fair Value Measurements [Member]
Warrant liability	82	361
Fair value of liabilities	2,975	3,488
Level 1 [Member]
Warrant liability
Fair value of liabilities
Level 2 [Member]
Warrant liability
Fair value of liabilities
Level 3 [Member]
Warrant liability	82	361
Fair value of liabilities	2,975	3,488
Asuran [Member]
Contingent consideration	2,893	3,127
Asuran [Member] | Fair Value Measurements [Member]
Contingent consideration	2,893	3,127
Asuran [Member] | Level 1 [Member]
Contingent consideration
Asuran [Member] | Level 2 [Member]
Contingent consideration
Asuran [Member] | Level 3 [Member]
Contingent consideration	$ 2,893	$ 3,127

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Beginning Balance	$ 3,488
Payments	(630)
Accretion	440
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	(323)
Ending Balance	2,975
Underwriter Warrants[Member]
Beginning Balance	361
Payments
Accretion
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	(279)
Ending Balance	82
Asuran [Member]
Beginning Balance	3,127
Payments	(630)
Accretion	440
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	(44)
Ending Balance	$ 2,893

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 500	$ 200

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Furniture and fixtures	$ 242	$ 62
Lab and office equipment	6,353	1,686
Computer equipment	339	172
Internal-use software	1,276	113
Leasehold improvements	506	175
Property and equipment	8,716	2,208
Less accumulated depreciation and amortization	(1,902)	(1,371)
Net property and equipment	$ 6,814	$ 837

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Details Narrative) - USD ($)	3 Months Ended										12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2019	Dec. 31, 2018	Jul. 15, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets											$ 15,600,000
Goodwills											8,433,000		$ 8,300,000
Identifiable intangible assets													$ 7,300,000
Amortization expense	$ 5,262,000	$ 5,178,000	$ 5,094,000	$ 4,500,000	$ 3,990,000	$ 3,480,000	$ 2,461,000	$ 1,951,000	$ 1,441,000	$ 118,000	$ 4,000,000	$ 3,600,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-lived Intangible Assets, Gross	$ 39,288	$ 31,988
Finite-lived Intangible Assets, Accumulated Amortization	(23,439)	(19,450)
Finite-lived Intangible Assets, Net Carrying Value	$ 15,849	12,538
CLIA Lab [Member]
Finite-lived Intangible Asset, Useful Life (Years)	2 years 3 months 19 days
Finite-lived Intangible Assets, Gross	$ 609	609
Asuragen Acquisition [Member] | Thyroid [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 8,519	8,519
RedPath Acquisition [Member] | Pancreas Test [Member]
Finite-lived Intangible Asset, Useful Life (Years)	7 years
Finite-lived Intangible Assets, Gross	$ 16,141	16,141
RedPath Acquisition [Member] | Barrett's Test [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 6,719	6,719
BioPharma Acquisition [Member] | Trademarks [Member]
Finite-lived Intangible Asset, Useful Life (Years)	10 years
Finite-lived Intangible Assets, Gross	$ 1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]
Finite-lived Intangible Asset, Useful Life (Years)	8 years
Finite-lived Intangible Assets, Gross	$ 5,700

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Schedule of Goodwill Carrying Valuel (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Balance Beginning
Goodwill acquired	8,273
Adjustments	160
Balance Ending	$ 8,433

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) $ in Thousands	Dec. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 4,871
2021	4,078
2022	2,156
2023	1,745
2024	$ 873

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 02, 2019
Lease liabilities	$ 3,916
Finance lease liabilities	$ 307
Operating lease term	1 year
ASU 2016-02 [Member]
Right-of-use lease assets		$ 2,400
Lease liabilities		2,500
Cumulative adjustment to opening accumulated deficit		$ 100
Operating lease term		2 years 8 months 12 days
Weighted average discount rate leases percentage		6.00%
ASU 2016-02 [Member] | BioPharma Acquisition [Member]
Right-of-use lease assets		$ 2,200
Lease liabilities		2,200
Finance lease assets		500
Finance lease liabilities		$ 500

Leases - Schedule of Financing

Leases - Schedule of Financing and Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Operating lease assets	$ 3,892
Total lease assets	4,890
Current financing lease liabilities	184
Current operating lease liabilities	1,321
Total current lease liabilities	1,505
Noncurrent financing lease liabilities	123
Noncurrent operating lease liabilities	2,591
Total long-term lease liabilities	2,714
Total lease liabilities	4,219
Property and Equipment, Net [Member]
Financing lease assets	998
Operating Lease Right of Use Assets [Member]
Operating lease assets	3,892
Other Accrued Expenses [Member]
Current financing lease liabilities	184
Current operating lease liabilities	1,321
Operating Lease Liabilities [Member]
Noncurrent financing lease liabilities	123
Noncurrent operating lease liabilities	$ 2,591

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating and Financing Lease Liabilties (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 1,472
2021	1,295
2022	1,223
2023	344
Total minimum lease payments	4,334
Less: amount of lease payments representing effects of discounting	418
Present value of future minimum lease payments	3,916
Less: current obligations under leases	1,321
Long-term lease obligations	2,591
2020	226
2021	120
2022	13
2023
Total minimum lease payments	359
Less: amount of lease payments representing effects of discounting	52
Present value of future minimum lease payments	307
Less: current obligations under leases	184
Long-term lease obligations	$ 123

Retirement Plans (Details Narra

Retirement Plans (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined contribution plan, maximum annual contributions per employee, percent	50.00%
Defined contribution plan, employer matching contribution, percent	100.00%
Defined contribution plan employer matching contribution at fifty percent	50.00%
Contribution expense	$ 300	$ 200
Minimum [Member]
Defined contribution plan, employer matching contribution, percent	3.00%
Defined contribution plan employer matching contribution at fifty percent	3.00%
Maximum [Member]
Defined contribution plan employer matching contribution at fifty percent	5.00%

Accrued Expenses and Long-term

Accrued Expenses and Long-term Liabilities - Schedule of Other Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued royalties	$ 1,934	$ 1,399
Indemnification liability		875
Contingent consideration	502	434
Operating lease liability	1,321
Financing lease liability	184
Deferred revenue	457
Payable to CGI	888
Accrued sales and marketing - diagnostics	197
Accrued lab costs - diagnostics	163	150
Accrued professional fees	1,399	758
Taxes payable	403	285
Unclaimed property	565	565
All others	1,463	682
Total other accrued expenses	$ 9,476	$ 5,148

Accrued Expenses and Long-ter_2

Accrued Expenses and Long-term Liabilities - Schedule of Long Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Warrant liability	$ 82	$ 361
Uncertain tax positions	4,081	3,838
Deferred revenue	269
Other	141	120
Total other long-term liabilities	$ 4,573	$ 4,319

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease expire date description	expire at various dates through June 2023
Total expense	$ 1,300	$ 700
Contractual obligations terms	1 year

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Contractual Obligation, Fiscal Year Maturity (Details) $ in Thousands	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease obligations, total	$ 4,334
Operating lease obligations, less than 1 year	1,472
Operating lease obligations, 1 to 3 years	2,518
Operating lease obligations, 3 to 5 years	344
Operating lease obligations, after 5 years
Operating leases future minimum, total	4,334
Operating leases future minimum, less than 1 year	1,472
Operating leases future minimum, 1 to 3 years	2,518
Operating leases future minimum, 3 to 5 years	344
Operating leases future minimum, after 5 years

Equity (Details Narrative)

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Oct. 16, 2019	Jul. 15, 2019	Jan. 25, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Sep. 20, 2019
Shares granted				132,545
Received net proceeds				$ 6,478
Proceeds from issuance of stock				$ 25,744
Preferred stock, shares issued				270	270
Preferred stock, shares outstanding				270	270
Underwriting Agreement [Member]
Aggregate of shares issued			9,333,334
Shares granted			1,400,000
Common stock price, per share			$ 7.50
Effective price per share			$ 6.975
Received net proceeds			$ 5,900
Security Purchase Agreement [Member] | Investor [Member]
Business combination consideration shares	130
Business combination consideration amount	$ 13,000
Security Purchase Agreement [Member] | Convertible Preferred Stock [Member]
Preferred price per share		$ 0.01
Preferred stock par/stated value		$ 100,000
Security Purchase Agreement [Member] | Convertible Preferred Stock [Member] | Maximum [Member]
Proceeds from preferred stock value		$ 27,000
Security Purchase Agreement [Member] | 60 Newly Created Series A Preferred Stock [Member]
Business combination consideration shares		60
Business combination consideration amount		$ 6,000
Security Purchase Agreement [Member] | 80 Newly Created Series A-1 Preferred Stock [Member]
Business combination consideration shares		80
Business combination consideration amount		$ 8,000
Proceeds from issuance of stock		$ 13,100
Equity Distribution Agreement [Member]
Received net proceeds						$ 2,000
Aggregate offering price							$ 4,800
Fixed percentage of commission							3.00%
Reverse stock split shares issued						97,817

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding and Warrants Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Warrants Issued	1,990,934
Warrants Exercised	(567,286)
Warrants Cancelled/Expired	(4,000)
Warrants	1,354,214	1,419,648
Private Placement Warrants[Member]
Description	Private Placement Warrants, issued January 25, 2017
Classification	Equity
Exercise Price	$ 46.90
Expiration Date	June 2022
Warrants Issued	85,500
Warrants Exercised
Warrants Cancelled/Expired
Warrants	85,500	85,500
RedPath Warrants[Member]
Description	RedPath Warrants, issued March 22, 2017
Classification	Equity
Exercise Price	$ 46.90
Expiration Date	September 2022
Warrants Issued	10,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	10,000	10,000
Underwriter Warrants[Member]
Description	Underwriters Warrants, issued June 21, 2017
Classification	Liability
Exercise Price	$ 13.20
Expiration Date	December 2022
Warrants Issued	57,500
Warrants Exercised
Warrants Cancelled/Expired	(4,000)
Warrants	53,500	53,500
Base & Overallotment Warrants [Member]
Description	Base & Overallotment Warrants, issued June 21, 2017
Classification	Equity
Exercise Price	$ 12.50
Expiration Date	June 2022
Warrants Issued	1,437,500
Warrants Exercised	(567,286)
Warrants Cancelled/Expired
Warrants	870,214	870,214
Vendor Warrants [Member]
Description	Vendor Warrants, issued August 6, 2017
Classification	Equity
Exercise Price	$ 12.50
Expiration Date	August 2020
Warrants Issued	15,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	15,000	15,000
Warrants Issued [Member]
Description	Warrants issued October 12, 2017
Classification	Equity
Exercise Price	$ 18
Expiration Date	April 2022
Warrants Issued	320,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	320,000	320,000
Underwriters Warrants [Member]
Description	Underwriters Warrants, issued January 25, 2019
Classification	Equity
Exercise Price	$ 9.40
Expiration Date	January 2022
Warrants Issued	65,434
Warrants Exercised
Warrants Cancelled/Expired
Warrants	65,434

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based compensation arrangements, options, grants in period, weighted average exercise price	$ 8.50	$ 9.30
Share-based compensation aggregate fair value of option	$ 500	$ 1,200
Weighted-average grant date fair value of options vested		$ 1.40
Aggregate fair value of restricted stock units	200	$ 100
Total unrecognized compensation cost related to unvested stock options and restricted stock units	$ 1,600
Stock Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, description	Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The Company granted stock options in 2017 which vest monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units ("RSUs") granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	2.34%	2.71%
Expected life	5 years 10 months 25 days	6 years
Expected volatility	128.58%	127.18%
Dividend yield	0.00%	0.00%

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
RSUs	$ 243	$ 301
Option	722	1,433
Total stock-based compensation expense	$ 965	$ 1,734

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Shares outstanding beginning balance | shares	288,950
Shares granted | shares	132,545
Shares exercised | shares
Shares forfeited or expired | shares	(5,817)
Shares outstanding ending balance | shares	415,678
Shares exercisable ending balance | shares	202,206
Shares vested and expected to vest | shares	402,921
Weighted average grant price outstanding beginning balance | $ / shares	$ 21.40
Weighted average grant price granted | $ / shares	9.50
Weighted average grant price forfeited or expired | $ / shares	387.10
Weighted average grant price outstanding ending balance | $ / shares	12.50
Weighted average grant price exercisable ending balance | $ / shares	15.20
Weighted average grant price vested and expected to vest | $ / shares	$ 12.60
Weighted average remaining contractual period outstanding beginning balance	8 years 9 months 29 days
Weighted average remaining contractual period granted	9 years 3 months 19 days
Weighted average remaining contractual period exercised	0 years
Weighted average remaining contractual period forfeited or expired	0 years
Weighted average remaining contractual period outstanding ending balance	8 years 5 months 12 days
Weighted average remaining contractual period exercisable ending balance	7 years 10 months 28 days
Weighted average remaining contractual period vested and expected to vest	8 years 5 months 5 days
Aggregate instrinsic value outstanding beginning balance | $
Aggregate instrinsic value granted | $
Aggregate instrinsic value exercised | $
Aggregate instrinsic value forfeited or expired | $
Aggregate instrinsic value outstanding ending balance | $
Aggregate instrinsic value exercisable ending balance | $
Aggregate instrinsic value vested and expected to vest | $

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Non Vested Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Non-vested Shares outstanding beginning balance	134,089
Non-vested Shares granted	132,545
Non-vested Shares vested	(53,150)
Non-vested Shares forfeited
Non-vested Shares outstanding ending balance	213,484	134,089
Non-vested weighted average grant date fair value outstanding beginning balance	$ 9.30
Non-vested weighted average grant date fair value granted	8.50	$ 9.30
Non-vested weighted average grant date fair value exercised	9
Non-vested weighted average grant date fair value forfeited
Non-vested weighted average grant date fair value outstanding ending balance	$ 8.80	$ 9.30

Stock-Based Compensation - Sc_5

Stock-Based Compensation - Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Non-vested Shares granted	1,990,934
Non-vested Shares Forfeited	4,000
Non-vested Aggregate Intrinsic Value Vested	$ 500	$ 1,200
Restricted Stock Units (RSUs) [Member]
Non-vested Shares beginning balance	36,224
Non-vested Shares granted	27,637
Non-vested Shares Vested	(14,486)
Non-vested Shares Forfeited
Non-vested Shares ending balance	49,375	36,224
Non-vested Weighted Average Grant Date Fair Value beginning balance	$ 11.70
Non-vested Weighted Average Grant Date Fair Value Granted	9.80
Non-vested Weighted Average Grant Date Fair Value Vested	13.70
Non-vested Weighted Average Grant Date Fair Value Forfeited
Non-vested Weighted Average Grant Date Fair Value Ending balance	$ 10	$ 11.70
Non-vested Average Remaining Vesting Period Beginning balance	1 year 4 months 13 days
Non-vested Average Remaining Vesting Period Granted	0 years
Non-vested Average Remaining Vesting Period Vested	0 years
Non-vested Average Remaining Vesting Period Forfeited	0 years
Non-vested Average Remaining Vesting Period Ending balance	1 year 1 month 9 days
Non-vested Aggregate Intrinsic Value Beginning balance	$ 289,758
Non-vested Aggregate Intrinsic Value Granted
Non-vested Aggregate Intrinsic Value Vested
Non-vested Aggregate Intrinsic Value Forfeited
Non-vested Aggregate Intrinsic Value Ending balance	$ 246,875	$ 289,758

Revenue Sources (Details Narrat

Revenue Sources (Details Narrative) - Sales Revenue, Net [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue from continuing operations	10.00%	10.00%
Medicare [Member]
Revenue from continuing operations	44.00%	41.00%

Revenue Sources - Schedule of R

Revenue Sources - Schedule of Revenue by Major Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 24,220	$ 21,896
Medicare Customer [Member]
Revenue	10,605	9,114
Commercial Payors Customer [Member]
Revenue	7,589	4,079
Client Billings Customer [Member]
Revenue	3,521	3,621
Medicare Advantage Customer [Member]
Revenue	$ 1,912	$ 3,011

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended								12 Months Ended		36 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Federal net income loss percentage									Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year.
Unrecognized tax benefits	$ 800,000				$ 800,000				$ 800,000	$ 800,000	$ 800,000
Income tax examination penalties and interest expense									300,000	200,000
Income tax examination penalties and interest accrued	3,300,000				$ 3,000,000				$ 3,300,000	$ 3,000,000	3,300,000
Income tax examination, description									The Tax Cuts and Jobs Act (the "TCJA") was enacted on December 22, 2017 and became effective for tax years beginning after December 31, 2017. The TCJA had significant changes to U.S. tax law, lowering U.S. corporate income tax rates, implementing a territorial tax system, imposing a one-time transition tax on deemed repatriated earnings of foreign subsidiaries and modified the taxation of other income and expense items. The TCJA reduces the U.S. corporate income tax rate from 34% to 21%, effective January 1, 2018. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 34% to 21% under the TCJA, we revalued deferred tax assets, net as of December 31, 2017.
Us corporate tax percentage									21.00%	21.00%
Deferred tax assets	22,768,303								$ 22,768,303		22,768,303
Valuation allowance	$ 22,768,303								22,768,303		$ 22,768,303
Common Stock [Member]
Number of common stock issued, shares	5,000		10,000	9,000	40,000	10,000	33,000	4,000			3,700,000
Preferred Stock [Member]
Number of common stock issued, shares											3,470,000
Federal [Member]
Operating loss carryforwards	$ 210,100,000								210,100,000		$ 210,100,000
State and Local Jurisdiction [Member]
Operating loss carryforwards	$ 92,200,000								$ 92,200,000		$ 92,200,000

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal	$ (46)	$ (2)
State		20
Total current	(46)	18
Federal	11
State	7
Total deferred	18
Benefit from income taxes	$ (28)	$ 18

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal net operating loss carryforwards	$ 44,152	$ 40,158
State net operating loss carryforwards	5,687	4,541
Compensation	1,399	1,100
Allowances and reserves	457	1,007
State taxes	848	794
Credit carryforward	229	234
163(j) interest	141
Leases	23
Deferred revenue	88	89
Property, plant and equipment		16
Gross deferred tax assets	53,024	47,939
Intangible assets	1,112	(44)
Property, plant and equipment	(263)
Valuation allowance	(53,891)	(47,895)
Deferred tax liability-net valuation allowance	$ (18)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
State income tax rate, net of Federal tax benefit	3.00%	2.90%
Meals and entertainment	(0.20%)	(0.30%)
Contingent consideration	0.00%	0.00%
Tax reform change	0.00%	0.00%
Valuation allowance	(23.80%)	(23.70%)
Other non-deductible	0.00%	(0.10%)
Naked credit	(0.10%)	0.00%
Discontinued operations allocation	0.20%	0.00%
Effective income tax rate	0.10%	(0.20%)

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Unrecognized tax benefits beggining balance	$ 794	$ 1,117
Additions for tax positions of prior years	54
Reductions for tax positions of prior years		(323)
Unrecognized tax benefits ending balance	$ 848	$ 794

Income Taxes - Schedule of Tax

Income Taxes - Schedule of Tax Years Subject to Examination (Details)	12 Months Ended
	Dec. 31, 2019
Federal [Member] | Earliest Tax Year [Member]
Open tax year	2015
Federal [Member] | Latest Tax Year [Member]
Open tax year	2019
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]
Open tax year	2014
State and Local Jurisdiction [Member] | Latest Tax Year [Member]
Open tax year	2019

Historical Basic and Diluted _3

Historical Basic and Diluted Net Loss Per Share - Schedule of Weighted Average Number of Shares (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Basic weighted average number of common shares	3,746,000	2,816,000
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	3,746,000	2,816,000

Historical Basic and Diluted _4

Historical Basic and Diluted Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities excluded from earning per share	1,885,000	1,679,000
Options [Member]
Antidilutive securities excluded from earning per share	416,000	283,000
Stock-Settled Stock Appreciation Rights (SARs) [Member]
Antidilutive securities excluded from earning per share		6,000
Restricted Stock Units (RSUs) [Member]
Antidilutive securities excluded from earning per share	49,000	36,000
Warrants [Member]
Antidilutive securities excluded from earning per share	1,420,000	1,354,000

Line of Credit (Details Narrati

Line of Credit (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 13, 2018
Line of credit		$ 3,000
Silicon Valley Bank [Member]
Line of credit	$ 850	3,000
Line of credit outstanding accounts receivable		$ 750
Line of credit facility, description	The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.	The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021
Line of credit, percentage	0.50%
Revolving Line facility fee monthly in arrears, percentage		0.35%
Line of credit, maturity date		May 2, 2022
Silicon Valley Bank [Member] | Prime Rate [Member]
Line of credit, percentage	5.00%	0.50%
Loan and Security Agreement [Member] | Silicon Valley Bank [Member]
Line of credit		$ 250		$ 4,000
Line of credit outstanding accounts receivable				3,750
Loan and Security Agreement [Member] | Silicon Valley Bank [Member] | Term Loan [Member]
Line of credit				$ 850

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Disclosure of Cash flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Supplemental Cash Flow Elements [Abstract]
Net cash used in operating activities of discontinued operations	$ (30)	$ (361)
Net cash provided by investing activities of discontinued operations
Cash paid for taxes	227	324
Cash paid for interest	170
Adoption of ASC 606		2,500
Prepaid stock grants issued to vendors		497
Adoption of ASC 842 - right of use asset
Adoption of ASC 842 - operating lease liability
Accrued financing costs	342
Accrued preferred dividends	$ 429

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

Apr. 21, 2020

Mar. 31, 2020

Jan. 15, 2020

Jan. 10, 2020

Jan. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2019

Apr. 20, 2020

Jul. 31, 2019

Subsequent Event [Line Items]

Number of shares sold in transaction

97,817

Preferred stock aggregate value

$ 73

$ 1

$ 594

$ 143

$ 285

$ 1

Preferred stock dividend percentage

6.00%

Letter of credit

$ 3,000

$ 3,000

$ 3,000

Proceeds from line of credit

$ 3,000

Preferred Stock [Member]

Subsequent Event [Line Items]

Aggregate of shares issued

3,470,000

Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Aggregate of shares issued

27,000

Preferred stock conversion price per shares

$ 0.60

Preferred stock adjusted conversion

6

Series A Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value

$ 0.01

$ 0.01

$ 0.01

Aggregate of shares issued

270

Preferred shares stated value

$ 100,000

$ 100,000

$ 100,000

Preferred stock conversion price per shares

0.80

Preferred stock adjusted conversion

$ 8

Security Purchase and Exchange Agreement [Member]

Subsequent Event [Line Items]

Letter of credit

$ 4,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Cash

$ 18,400

Description for loans to qualifying businesses value and its term

As of April 20, 2020, the Company's PPP loan has not yet been approved, pending new legislation increasing the pool. The PPP provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. If the Company is successful in obtaining a PPP loan, we intend to use the proceeds for purposes consistent with the PPP and expect to meet the conditions for forgiveness of the loan.

Payment of line of credit

$ 3,400

Letter of credit

$ 350

Proceeds from line of credit

$ 600

Subsequent Event [Member] | Preferred Stock [Member]

Subsequent Event [Line Items]

Number of shares sold in transaction

20,000

Company achieve revenue target

$ 34,000

Preferred shares voting rights description

In connection with the Company's application for the PPP loan, both Ampersand and 1315 Capital Ampersand consented to, and agreed to vote (by proxy or otherwise) their preferred shares in favor of any "Fundamental Action" taken by the Company as determined by the Company's Board of Directors. "Fundamental Actions" include the Company's ability to a) authorize, create or issue any debt securities for borrowed money or funded debt; b) merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess of $20 million; c) transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Company or any of its direct or indirect subsidiaries, other than those accomplished in the ordinary course of business; d) declare or pay any cash dividend or make any cash distribution on any equity interests of the Company other than the Series B Shares; d) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities, and e) change any accounting methods or practices of the Company, except for those changes required by GAAP or applicable regulatory agencies or authorities.

Payment of line of credit

$ 3,000

Subsequent Event [Member] | Centers for Medicare & Medicaid Services [Member]

Subsequent Event [Line Items]

Proceeds from loans payable

2,100

Loans payable

$ 2,100

Subsequent Event [Member] | Department of Health and Human Services [Member]

Subsequent Event [Line Items]

Proceeds from loans payable

650

Loans payable

650

Subsequent Event [Member] | Agreement Agent [Member]

Subsequent Event [Line Items]

Number of shares sold in transaction

80,341

Sale of stock transaction amount

$ 500

Subsequent Event [Member] | Reverse Stock Split [Member]

Subsequent Event [Line Items]

Reverse stock split, description

Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. Our common stock began trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on January 15, 2020.

Subsequent Event [Member] | Small Business Administration [Member]

Subsequent Event [Line Items]

Loans payable

3,500

Subsequent Event [Member] | Department of Health and Human Services (HSS) [Member]

Subsequent Event [Line Items]

Loans payable

650

Subsequent Event [Member] | Security Purchase and Exchange Agreement [Member] | Series B Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock aggregate value

$ 20,000

Subsequent Event [Member] | Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value

$ 0.01

issuance price of Preferred Stock

$ 1,000

Subsequent Event [Member] | Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member]

Subsequent Event [Line Items]

Preferred stock aggregate value

$ 19,000

Aggregate of shares issued

19,000

Subsequent Event [Member] | Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand 2018 Limited Partnership [Member]

Subsequent Event [Line Items]

Preferred stock aggregate value

$ 1,000

Aggregate of shares issued

1,000

Subsequent Event [Member] | Credit Facility [Member]

Subsequent Event [Line Items]

Cash

3,400

Subsequent Event [Member] | Credit Facility [Member] | Minimum [Member]

Subsequent Event [Line Items]

Cash

4,000

4,000

Subsequent Event [Member] | Credit Facility [Member] | Maximum [Member]

Subsequent Event [Line Items]

Cash

$ 8,000

$ 8,000

Schedule II - Schedule of Valua

Schedule II - Schedule of Valuation and Qualifying Accounts Disclosure (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Allowance for Doubtful Notes [Member]
Balance at Beginning of Period		$ 869	$ 869
Additions (Reductions) Charged to Operations
Deductions Other	[1]
Balance at end of Period		869	869
Tax Valuation Allowance [Member]
Balance at Beginning of Period		47,895	46,308
Additions (Reductions) Charged to Operations
Deductions Other	[1]	5,996	1,587
Balance at end of Period		53,891	47,895
Allowance for Doubtful Accounts [Member]
Balance at Beginning of Period
Additions (Reductions) Charged to Operations
Deductions Other	[1]	25
Balance at end of Period		$ 25
[1]	Includes payments and actual write offs, as well as changes in estimates in the reserves.